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New psychoactive substances (NPS) are a heterogeneous and rapidly evolving class of
molecules available on the global illicit drug market (e.g smart shops, internet, “dark
net”) as a substitute for controlled substances. The use of NPS, mainly consumed
along with other drugs of abuse and/or alcohol, has resulted in a significantly growing
number of mortality and emergency admissions for overdoses, as reported by several
poison centers from all over the world. The fact that the number of NPS have more
than doubled over the last 10 years, is a critical challenge to governments, the scientific
community, and civil society [EMCDDA (European Drug Report), 2014; UNODC, 2014b;
Trends and developments]. The chemical structure (phenethylamines, piperazines,
cathinones, tryptamines, synthetic cannabinoids) of NPS and their pharmacological
and clinical effects (hallucinogenic, anesthetic, dissociative, depressant) help classify
them into different categories. In the recent past, 50% of newly identified NPS have
been classified as synthetic cannabinoids followed by new phenethylamines (17%)
(UNODC, 2014b). Besides peripheral toxicological effects, many NPS seem to have
addictive properties. Behavioral, neurochemical, and electrophysiological evidence can
help in detecting them. This manuscript will review existing literature about the addictive
and rewarding properties of the most popular NPS classes: cannabimimetics (JWH,
HU, CP series) and amphetamine-like stimulants (amphetamine, methamphetamine,
methcathinone, and MDMA analogs). Moreover, the review will include recent data from
our lab which links JWH-018, a CB1 and CB2 agonist more potent than 91 -THC,
to other cannabinoids with known abuse potential, and to other classes of abused
drugs that increase dopamine signaling in the Nucleus Accumbens (NAc) shell. Thus the
neurochemical mechanisms that produce the rewarding properties of JWH-018, which
most likely contributes to the greater incidence of dependence associated with “Spice”
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use, will be described (De Luca et al., 2015a). Considering the growing evidence of a
widespread use of NPS, this review will be useful to understand the new trends in the
field of drug reward and drug addiction by revealing the rewarding properties of NPS, and
will be helpful to gather reliable data regarding the abuse potential of these compounds.
Keywords: novel psychoactive substances, NPS, cannabinoids, psychostimulants, JWH-018, Spice
INTRODUCTION
Over the last decade, New Psychoactive Substances (NPS)
have become a global phenomenon. The emergence of these
substances have been reported in almost 100 countries and
territories, and more than 500 NPS have been identified
worldwide based on reports by national governments, as well as
the EU, and international institutions (UNODC, 2014a, 2015)
(Figure 1). In 2014, in Europe alone, 101 NPS have been detected
showing an increase of 25%, as compared to 2013 [EMCDDA
(New psychoactive substances in Europe), 2015b]. NPS are able
to mimic the effects of controlled substances and are mainly
synthetic cannabinoids, stimulants, hallucinogens, and opioids.
Previous studies show that the use of NPS occurs
among different subject groups: school students, partygoers,
psychonauts, prisoners, and injecting drug users. Motivations
for use include factors such as legal status, availability, and cost,
as well as the desire to avoid detection and user preferences for
particular pharmacological properties [González et al., 2013;
Helander et al., 2013, 2014; EMCDDA (European Drug Report),
2015a; EMCDDA (New psychoactive substances in Europe),
2015b]. Although global research is not available yet about NPS,
prevalence of use among the population, single national surveys
(with respect to substances and subpopulations) show that the
use of NPS amongst the general adult population is relatively
low compared with the use of other illicit drugs. However,
adolescents use more NPS than illicit drugs mostly because many
of them are legal and easily available on the web [Drug Policy
Department Italian Presidency of the Council of Ministers,
2014; Fraser, 2014; Kikura-Hanajiri et al., 2014; EMCDDA (New
FIGURE 1 | Number of NPS reported worldwide (2009–2014).
Adapted from UNODC (2014a). NPS reported for the first time
Known NPS reported.
psychoactive substances in Europe), 2015b; Hondebrink et al.,
2015; Palamar et al., 2015; Wood et al., 2015].
Similar to many known illicit drugs, NPS can cause severe
physical and psychological symptoms that can even result in
death [Drug Policy Department Italian Presidency of the Council
of Ministers, 2013b; Fraser, 2014; EMCDDA (European Drug
Report), 2015a; UNODC, 2015]. A recent analysis by the
European Drug Emergencies Network, monitoring emergency
admissions in the last 5 years in 10 EU countries, found that
9% of all drug-related emergencies involved NPS, primarily
synthetic cannabinoids and cathinones (Wood et al., 2014).
Consequently, there is increasing evidence that NPS play a
great role in hospital emergencies and some drug-induced
deaths [EMCDDA (European Drug Report), 2015a]. However,
the analytical detection of NPS for emergency services is not
technically available so far; their recognition by means of second
level analysis requires standards solution, methodologies and
analytical equipment not accessible to every laboratory yet [Drug
Policy Department Italian Presidency of the Council ofMinisters,
2013b; UNODC, 2014a; EMCDDA (European Drug Report),
2015a]. Therefore, their identification in biological samples, as
well as in seized or collected samples, represents one major
difficulty.
Notably, the internet is an important marketplace for the sale
of NPS. Evidence is emerging of so-called “gray marketplaces”-
online sites selling NPS which operate on both the surface as well
as the deep web (Deluca et al., 2012; Drug Policy Department
Italian Presidency of the Council of Ministers, 2013b; Burns et al.,
2014; Corazza et al., 2014). Therefore, NPS can be sold via the
internet to everyone, including young, underage teenagers, with
complete anonymity and an easy avoidance of law enforcement
and health controls [Drug Policy Department Italian Presidency
of the Council of Ministers, 2013b; UNODC, 2014a; EMCDDA
(European Drug Report), 2015a]. The growth of online and
virtual drug markets strongly contributes to the uncontrolled
widespread use of these substances, increasing health risks for
consumers, and challenging drug control policies.
The largest increase in terms of newly reported NPS
involves synthetic cannabinoids, synthetic cathinones, and
phenethylamines [EMCDDA (European Drug Report), 2015a;
EMCDDA (New psychoactive substances in Europe), 2015b].
The first synthetic cannabinoids were identified in 2008 in
preparations called “herbal mixtures” or “herbal blends” (i.e.,
Spice) and sold as incense or air fresheners. Their effects
are similar, if not superior, to those caused by cannabis
consumption (Hohmann et al., 2014; Khullar et al., 2014;
Mills et al., 2015). Recently, a survey of the use of synthetic
cannabinoids among US students showed that Spice products
were the second most used drug after marijuana, with a
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prevalence of 7.4–7.9% in those aged between 15 and 18 years
(Johnston et al., 2013). Adolescence, a critical developmental
period commonly associated with an increase in drug abuse
in the human population, may be a stage of particular
vulnerability to the effects of the new psychoactive drugs
(Johnston et al., 2013). In fact, most of the brain receptor
systems have been shown to mature slowly, reaching maximal
levels around age 20. Indeed, the use of these drugs might
influence neurodevelopment inducing psychiatric disorders or
other mental deficits (Paus, 2005; Sussman et al., 2008).
Several NPS such as mephedrone, pentedrone and MDPV
which mimic the effects of amphetamine-like stimulants (ATS),
can be classified as synthetic cathinones with stimulant and
empathogenic properties, or as phenethylamines which can
induce stimulant and hallucinogenic effects (UNODC, 2014a,
2015). Similar to other NPS, synthetic cannabinoids and ATS are
largely available online and are often sold as research chemical
components. They are mainly produced in Eastern Europe,
Central Asia and China, and then shipped and sold to Europe
and the USA (UNODC, 2015).
Currently, not all NPS are under international control.
Many countries worldwide have established permanent control
measures for some substances or issued temporary bans
[EMCDDA (New psychoactive substances in Europe), 2015b;
UNODC, 2015]. Only a few NPS have been reviewed by
the mechanisms established under the international drug
conventions. Existing laws covering issues unrelated to
controlled drugs, such as consumer safety legislation, have
been used in some countries such as Poland and UK; in
others (Hungary, Finland, Italy, France, Denmark, etc.)
existing drug laws or processes have been extended or adapted;
additionally, in Ireland, Austria, Portugal, Romania, and
Sweden new legislation has been designed [EMCDDA
(New psychoactive substances in Europe), 2015b; UNODC,
2015].
The forensic identification of NPS is very difficult. These
may concern the lack of knowledge on NPS available
to the professionals performing analytical analysis. In
addition, analytical methodologies are still not sufficient
to detect the presence of all of the NPS in the analyzed
samples and many laboratories lack appropriate analytical
equipment for their recognition (Drug Policy Department
Italian Presidency of the Council of Ministers, 2013a).
These are all important aspects to take into account when
considering the legal, health, and social consequences related
to NPS.
To date, several behavioral, neurochemical, and
electrophysiological studies have helped us to understand
the pharmacological mechanisms of action of NPS. However,
many of them have been focused on the acute toxicological
consequences of NPS use. As they are relatively new and
novel, there are no epidemiological studies to show the
long-term effects of these psychoactive compounds. Also,
there is not a lot of evidence on the addictive properties
of NPS.
This work has been divided into two main parts based on
pharmacological classification of the most popular and public
health-concerning NPS classes: amphetamine-like stimulants
and cannabimimetic drugs. Moreover, specific references to
recent papers by the authors have been presented. A thorough
analysis of the rewarding and reinforcing properties of NPS
and their abuse liability will hopefully, provide to be useful for
understanding the new disturbing trends in the field of drug
addiction and provide strategies to tackle this growing problem.
NPS: FROM CHEMISTRY TO
PHARMACOLOGICAL EFFECTS
NPS can be divided into six chemical classes (Martinotti
et al., 2015; Schifano et al., 2015): phenethylamines,
piperazines, tryptamines, synthetic cathinones, alkylindoles
(synthetic cannabinoids) and arylcyclohexylamines
(see Table 1). Alternatively, a different classification
is based on pharmacological and clinical effects:
stimulants, entactogens, hallucinogens, and cannabis-like
compounds.
Phenethylamines, piperazines, tryptamines, and synthetic
catinones exhibit stimulant and hallucinogenic effects,
making up the distinct class of entactogens, which are
described as psychoactive substances that enhance feelings
of empathy, love, and emotional closeness to others (Schifano
et al., 2007). Entactogens can be chemically divided into
phenethylamines, amphetamines, synthetic cathinones,
piperazines, pipradrols/piperidines, aminoindanes, benzofurans,
and tryptamines (see Table 2). Stimulant drugs usually inhibit
monoamine reuptake, increasing the quantity of noradrenaline,
dopamine and serotonin in the synaptic cleft leading to
sympathomimetic effects (Schifano, 2013). Phenethylamines are
synthetic compounds commercially known as “party pills” (e.g.,
tablets of different colors/shapes, capsules, powder/crystal). They
act on serotoninergic receptors leading to psychedelic effects and
some of them inhibit the monoamine reuptake as well (Nelson
et al., 2014); 3,4-methylenedioxy-methamphetamine (MDMA),
widely known as “ecstasy,” is one of the most popular drugs
among young people because of its stimulant effects. But, recently
a growing use of new dangerous molecules on the recreational
drug scene, such as 2C and its derivatives (e.g., “N-Bomb,”
“B-Fly,” and “Dr. Death”), 2-D series drugs, 3C-bromo-
Dragonfly, 4-MTA, 6-APB, 4,4′-DMAR and MPA, that are novel
derivatives of classic psychedelic phenethylamines/MDMA-
like drugs (Nelson et al., 2014) has been reported; several
cases of intoxications have been reported with symptoms
such as hypertension, vomiting, hyperthermia, convulsions,
dissociation, hallucinations, respiratory deficits, liver, and kidney
failure and death in case of overdose (Winstock and Schifano,
2009; Schifano et al., 2010; Corazza et al., 2011; Dean et al.,
2013; Bersani et al., 2014; Le Roux et al., 2015; Maas et al.,
2015). The lead compound in piperazines, N-Benzylpiperazin
(BZP), has a typical central nervous system stimulant structure
so it triggers the release of dopamine and norepinephrine
and inhibits the uptake of dopamine, norepinephrine and
serotonin (Smith et al., 2015). Although BZP is structurally
similar to amphetamine, it is reported to have only one-tenth
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TABLE 1 | New Psychoactive Substances (NPS) classification.
Chemical class Pharmacological effects References
Phenethylamines Serotoninergic receptor agonists that cause psychedelic effects and inhibit monoamine reuptake Nelson et al., 2014
Effects: Hypertension, vomiting, hyperthermia, convulsions, dissociation, hallucinations, respiratory
deficits, liver and kidney failure, and death in case of overdose
Winstock and Schifano, 2009;
Schifano et al., 2010; Corazza
et al., 2011; Bersani et al., 2014
Piperazines Stimulants that promote the release of dopamine and noradrenaline and inhibits the uptake of
monoamines
Kersten and McLaughlin, 2015;
Smith et al., 2015
Effects: Hyperthermia, convulsions, and kidney failure; hallucinations and death have been reported at
high doses
Tryptamines 5HT2A receptor agonists and serotonin reuptake inhibitors Lessin et al., 1965; Nichols, 2004;
Sogawa et al., 2007; Fantegrossi
et al., 2008; Cozzi et al., 2009;
Fontanilla et al., 2010Effects: Visual hallucinations, alterations in sensory perception, depersonalization
Synthetic cathinones Sympathomimetic drugs that act on serotonin, dopamine, and noradreline pathways Corkery et al., 2012, 2014;
Schifano et al., 2012; Loi et al.,
2015Effects: Agitation, restlessness, vertigo, abdominal pain, paranoia, rhabdomyolysis, convulsions, and
death
Synthetic cannabinoids CB1 and CB2 receptors agonists displaying higher affinity, efficacy and potency compared to 19-THC Fattore and Fratta, 2011; Brents
and Prather, 2014; De Luca et al.,
2015a,b
Effects: Euphoria, anxiolytic, and antidepressant-like effects, paranoia, tachycardia, panic, convulsions,
psychosis, visual/auditory hallucinations, vomiting, and seizures
Hermanns-Clausen et al., 2013;
Winstock and Barratt, 2013
Arylcyclohexylamine Dissociative anesthetics that act as 5HT2A agonist and NMDA receptor antagonist and show high
affinity for opioid receptors
Nishimura and Sato, 1999; ACMD
(Advisory Council on the Misuse of
Drugs), 2013; Schifano et al., 2015Effects: Distort perceptions of sight and sound, dissociation from the environment and selfwithout
hallucinations
the potency (Wikström et al., 2004). However, at higher dosages,
hallucinations can be reported as well (Kersten and McLaughlin,
2015). Before legal restrictions were placed on it, BZP was used
as a safe alternative to amphetamines such as MDMA (Monteiro
et al., 2013). Tryptamines (the most common is the lysergic
acid diethylamide-LSD) are a group of monoamine alkaloids,
very similar to the endogenous neurotransmitter serotonin
(5-hydroxytryptamine, 5-HT) (Tittarelli et al., 2015), so they
act both as 5HT2A receptor agonists and serotonin reuptake
inhibitors (Lessin et al., 1965; Nichols, 2004; Fantegrossi et al.,
2008; Cozzi et al., 2009; Fontanilla et al., 2010) provoking
visual hallucinations, alterations in sensory perception, and
depersonalization (Sogawa et al., 2007); novel tryptamines,
as 5-MeO-AMT or 5-MeO-DMT, continue to appear on the
online drug market and on the “dark net” (Araújo et al., 2015;
Schifano et al., 2015; Teixeira-Gomes et al., 2014). Synthetic
cathinones (mephedrone, methylone,butylone, MDPV, and
α-PVP) are structural analogs of cathinones (a molecule
present in the psychoactive plant Khat) and are available
in tablets, capsules, powder/crystal and generally labeled as
“bath salts” or “plant fertilizers” (Fass et al., 2012; German
et al., 2014; Valente et al., 2014; Karila et al., 2015). Clinical
effects most commonly reported with cathinones include
anxiety, impaired concentration and memory, irritation of
the nasal mucosa, headache, tachycardia, and hypertension.
The typical clinical symptoms are indistinguishable from
the acute effects of MDMA or cocaine (Prosser and Nelson,
2012; Baumann et al., 2013; Valente et al., 2014); among their
psychoactive effects, agitation, restlessness, vertigo, abdominal
pain, paranoia, rhabdomyolysis, convulsions, and death are
included (Corkery et al., 2012, 2014; Schifano et al., 2012; Loi
et al., 2015).
Synthetic cannabinoids belong to the alkylindoles and
cyclohexylphenos classes which show high affinity for CB1 and
CB2 cannabinoid receptors and act like 19-THC but with
prolonged psychoactive effects and more side effects (Fattore and
Fratta, 2011; Brents and Prather, 2014). As shown in Figure 2,
they can be divided into naphtoylindoles (e.g., JWH- 018,
JWH-073, JWH-210, WIN-55212), phenylacetylindoles (e.g.,
JWH-250 e JWH-251), benzoylindoles (e.g., WIN-48,098, AM-
694, RSC-4), cyclohexylphenols (e.g., CP-47497, CP-55940, CP-
55244) (Smith et al., 2015). They are generally consumed by
inhalation through the consumption of cigarettes containing
herbal substances as well as these synthetic molecules to obtain
euphoria, anxiolytic, and antidepressant-like effects. However,
reports presented by the EMCDDA (2009a) and by the
Italian Early Warning System – N.E.W.S. (Anti-drug Policies
Department) have shown effects like paranoia, tachycardia,
Frontiers in Neuroscience | www.frontiersin.org 4 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
TABLE 2 | Chemical classes of stimulant drugs.
Chemical group Representatives
Usual name Chemical name References
Phenethylamines 2-PEA 2-phenylethanamine Teixeira-Gomes et al., 2014
DMMA 2-(3,4-dimethoxyphenyl)-Nmethylpropan-2-amine
DMA N,N-dimethyl-1-phenylpropan-2-amine UNODC, 2013
β-Me-PEA 2-phenylpropan-1-amine
Phenpromethamine N-methyl-2-phenylpropan-1-amine Liechti, 2015
Schifano et al., 2015
Amphetamines PMMA 1-(4-methoxyphenyl)-N-methylpropan-2-amine Iversen et al., 2014
PMA 1-(4-methoxyphenyl)propan-2-amine
4-FMA 1-(4-fluorophenyl)-N-methylpropan-2-amine Zawilska, 2015
4-CA 1-(4-chlorophenyl)propan-2-amine
2-FA 1-(2-fluorophenyl)propan-2-amine Simmler et al., 2014
2-FMA 1-(2-fluorophenyl)-N-methylpropan-2-amine
Fenfluramine 3-trifluoromethyl-N-ethylamphetamine
Synthetic cathinones or beta-keto (bk)
amphetamines
4-MMC (RS)-1-(4-methylphenyl)-2-methylaminopropan-1-one Baumann et al., 2013
4-EMC 1-(4-ethylphenyl)-2-(methylamino)propan-1-one
3,4-DMMC 1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one Kelly, 2011
Pentedrone 2-(methylamino)-1-phenylpentan-1-one
Mephedrone 2-(methylamino)-1-phenylpentan-1-one Coppola and Mondola,
2012
Metilone 1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one
MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one Paillet-Loilier et al., 2014
αPVP 1-phenyl-2-pyrrolidin-1-ylpentan-1-one
bk-PMMA 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one Schifano et al., 2015
Simmler et al., 2013
Piperazines BZP N-benzylpiperazine Iversen et al., 2014
pCPP 1-(4-chlorophenyl)-piperazine
mCPP 1-(3-chlorophenyl)-piperazine Zawilska, 2015
2C-B-BZP 1-[(4-bromo-2,5-dimethoxyphenyl)methyl]piperazine
TFMPP 1-(3-trifluoromethylphenyl)-piperazine UNODC, 2013
MeOPP 4-methoxyphenylpiperazine
pFPP 4-fluorophenylpiperazine
Pipradrols/Piperidines 2-DPMP 2-(Diphenylmethyl)piperidine Zawilska, 2015
desoxy-D2PM 2-(Diphenylmethyl)pirrolidine
Liechti, 2015
UNODC, 2013
Aminoidanes 2-AI 2,3-dihydro-1H-inden-2-amine Iversen et al., 2014
5-IAI 5-iodo-2,3-dihydro-1H-inden-2-amine
MDAI 6,7-Dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine UNODC, 2013
MMDAI 5,6-Methylenedioxy-N-methyl-2-aminoindane
MDAT 6,7- Methylenedioxy-2-aminotetralin
(Continued)
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TABLE 2 | Continued
Chemical group Representatives
Usual name Chemical name References
Benzofurans 5-APB 5-(2-aminopropyl)benzofuran Iversen et al., 2013
5-APDB 1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine
5-MAPB 1-(benzofuran-5-yl)-N-methylpropan-2-amine Iversen et al., 2014
6-APB 6-(2-aminopropyl)benzofuran
6-APDB 1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine Corkery et al., 2013
Tryptamines AMT 1-(1H-indol-3-yl)propan-2-amine Schifano et al., 2015
5-IT, 5-API 1-(1H-indol-5-yl)propan-2-amine
5-APDI 1-(2,3-Dihydro-1H-inden-5-yl)-2-propanamine Teixeira-Gomes et al., 2014
4-AcO-DPT 4-Acetoxy-N,N-dipropyltryptamine
5-MeO-DPT 5-methoxy-N,N-dipropyltryptamine Araújo et al., 2015
4-AcO-DMT 4-acetoxy-N,N-dimethyltryptamine
4-AcO-DALT 4-Acetoxy-N,N-diallyltryptamine
5-MeO-AMT 5-methoxy-α-methyltryptamine
5-MeO-DMT 5-metossi-N,N-dimetiltriptamina
2C Agents-substituted phenylethylamines 2C-H 2,5-dimethoxyphenethylamine Eshleman et al., 2014
2C-B 4-bromo-2,5-dimethoxyphenethylamine
2C-E 2,5-dimethoxy-4-ethylphenethylamine Schifano et al., 2015
2C-N 2,5-Dimethoxy-4-nitrophenethylamine
2C-G 2-(2,5-dimethoxy-3,4-dimethylphenyl)ethanamine Welter-Luedeke and Maurer,
2015
2D Agents-substituted phenylethylamines DOI 1-(4-iodo-2,5-dimethoxyphenyl)-propan-2-amine Zawilska, 2015
DOC 1-(4-chloro-2,5-dimethoxyphenyl)-propan-2-amine
DOB 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine Gatch et al., 2009
DOM 2,5-Dimethoxy-4-methylamphetamine
NBome Agents-substituted
phenylethylamines
25H-NBOMe 1-(2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine
Zawilska, 2015
25I-NBOMe 4-iodo-2,5-dimethoxy-N-(2-
methoxybenzyl)phenethylamine
25B-NBOMe 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine
Schifano et al., 2015
25E-NBOMe 2-(2,5-dimethoxy-4-ethylphenyl)-N-(2-
methoxybenzyl)ethanamine
25N-NBOMe 2-(2,5-Dimethoxy-4-nitrophenyl)-N-(2-
methoxybenzyl)ethanamine
Kyriakou et al., 2015
panic, convulsions, psychosis, visual/auditory hallucinations,
vomiting, and seizures (Hermanns-Clausen et al., 2013;Winstock
and Barratt, 2013).
Finally, arylcyclohexylamine (ketamine, phencyclidine-
PCP and methoxetamine) are dissociative anesthetics that
distort perceptions of sight and sound and produce feelings
of detachment (or dissociation) from the environment and
self without hallucinations [Nishimura and Sato, 1999;
ACMD (Advisory Council on the Misuse of Drugs), 2013].
Although present in the classification, the rewarding properties
of the latter group will not be discussed in this review
paper.
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FIGURE 2 | Number of NPS reported by substance group in 2014.
Adapted from UNODC (2014a).
HUMAN AND ANIMAL STUDIES ON
AMPHETAMINE-LIKE STIMULANTS
EFFECTS: PSYCHOACTIVE EFFECTS,
COGNITIVE DEFICITS, EMOTIONAL
ALTERATIONS, AND DEPENDENCE
In the second part of the 90s, a global trend of escalating
amphetamine-like stimulant use was observed and synthetic
tryptamines appeared on illicit drugmarkets. Instead of replacing
or displacing MDMA and cocaine, mephedrone, and other NPS
from this group appear to have been added to the established
repertoire of psychostimulant narcotics (Sanders et al., 2008;
Zawilska, 2015).
In animal models of addiction, cathinones have displayed
potential rewarding and reinforcing effects. For example,
mephedrone produces conditioned place preference (CPP),
facilitates intracranial self-stimulation and is self-administered
in rats (Hadlock et al., 2011; Lisek et al., 2012; Motbey et al.,
2013; Bonano et al., 2014; Gregg et al., 2015). Prior studies
demonstrated that MDPV and methylone, another synthetic
cathinone, increase locomotor activity in rodents (López-Arnau
et al., 2012; Marusich et al., 2012; Aarde et al., 2013; Gatch
et al., 2013) and also enhance intracranial self-stimulation
(Watterson et al., 2012, 2014; Bonano et al., 2014) and
engender conditioned place preference (Karlsson et al., 2014),
effects that are indicators of high abuse potential (Schindler
et al., 2015). This evidence suggests that each compound
could produce behavioral effects consistent with psychostimulant
drugs displaying high abuse liability, possibly higher than
amphetamine. In fact, in rats trained to self-administer MDPV or
methamphetamine, dose-substitution studies demonstrated that
behavior was dose-sensitive for both drugs, but MDPV showed
greater potency and efficacy than methamphetamine (Paillet-
Loilier et al., 2014). Moreover, in mice models, mephedrone,
methylone, and MDPV produce CPP equal or higher than
amphetamine, strongly suggesting their addictive properties
(Karlsson et al., 2014). In addition, MDMA, methylone, and
mephedrone are self-administered in female rats with a higher
intake in mephedrone-trained rats compared to methylone-
trained animals. This seems to suggest that mephedrone might
have greater reinforcing effects compared to methylone or
MDMA (Creehan et al., 2015), despite their shared mechanism
of action. They are non-selective transporter substrates that
increase the release of dopamine, norepinephrine and 5-HT in
vitro (Baumann et al., 2012; Eshleman et al., 2013; Simmler
et al., 2013). Importantly, the 5-HT-releasing ability of these
drugs is more prevalent than their effects on dopamine in vivo
(Baumann et al., 2008, 2012; Kehr et al., 2011; Wright et al., 2012)
suggesting empathogen-like effects. Such findings indicate that
self-administration of MDMA-like drugs is influenced by 5-HT
release, but also drug pharmacokinetics, effects on noradrenergic
systems, or non-transporter sites of action (Schindler et al., 2015).
In humans, synthetic cathinones produce psychotropic effects
similar to MDMA and cocaine (Simmler et al., 2013). The
typical dose range varies according to the different cathinone
derivatives. However, according to information released from
users in drug forums, where people discuss their experiences with
recreational drugs (e.g., “Drugs-Forum,” “Urban 75,” “Erowid”),
they usually start with a small dose and gradually increase it. This
is in line with scientific reports which show that an excessive
increase of noradrenergic signals could promote the onset of
adverse effects and that the potency of a substance to activate the
noradrenergic system is inversely correlated to the doses typically
used recreationally (Simmler et al., 2013). All cathinones exhibit
higher dopaminergic activity when compared with their non β-
keto amphetamines analogs. Recent studies of themechanisms by
which b-ketoamphetamines interact with DAT, offer significant
insight into why these drugs have such divergent effects on
neurotoxicity. “Bath salts” have been classified as substrates and
non-substrates based on whether or not they are transported by
the DAT (Anneken et al., 2015). This increased dopaminergic
property of the cathinones suggests higher stimulant-type effects
and a greater risk for dependence (Aarde et al., 2013). Stimulant
and entactogenic properties are typical of cathinones. In fact,
desired or pleasant effects most often described by users include
euphoria, intensification of sensory senses, increased sociability,
increased energy, mental stimulation, empathy connection,
openness, increased sensory perception, decreased inhibition,
and sexual arousal; but side effects such as cognitive confusion,
cognitive impairment, psychiatric irritability, aggression that
sometimes progresses to violent or even criminal behavior,
and self-destructive behavior have also been reported [IACP
(International Association of Chiefs of Police), 2012]. MDPV
and mephedrone have been directly implicated in a number of
fatalities in medical literature. In one case involving MDPV, the
cause of death was consistent with excited delirium syndrome,
a condition associated with stimulant drug overdose and
attributable to excessive dopaminergic transmission (Baumann
et al., 2012).
However, amphetamine remains the prototype of
psychostimulants causing agitation, insomnia, loss of appetite
and, at higher doses, “amphetamines psychosis” characterized
by paranoia, hallucinations and delusion (Iversen et al.,
2014). In experimental animals, low doses of amphetamine
cause hyperactivity and higher doses lead to stereotyped
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FIGURE 3 | Chemical structures of Synthetic Cannabinoids.
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repetitive behaviors (Whelpton, 2007). The neurotoxic effects
of amphetamines has been vastly studied and their ability to
damage brain monoaminergic cells was shown by long-term
deficits in dopaminergic and serotoninergic systems in several
brain areas of animals (Teixeira-Gomes et al., 2014). One of
the major neurotoxic actions of amphetamines observed in
laboratory animals is the sustained depletion of monoamine
brain levels. In addition to the damage to dopaminergic and
serotoninergic neuronal systems, amphetamines can also
induce neuronal death. For example, in several studies, MDMA
administration in mice and rats produced neuronal death in
several brain areas including the cortex, hippocampus, amygdala,
ventromedial/ventrolateral thalamus, and teniatecta (Teixeira-
Gomes et al., 2014). MDMA is still one of the most widely used
recreational drugs and many NPS were designed to mimic its
effects or as substitutes for MDMA in ecstasy pills.
The potency of abused psychostimulants to activate the brain
reward circuitry increases the risk of potential for abuse and
addiction in humans (Table 3). In contrast, a relative activation
of the serotonin system would be linked to a reduction in
abuse potential. Thus, the DAT/SERT inhibition ratio and
dopamine/serotonin release potency has been proposed to
predict the effects of psychostimulants in humans (Paillet-Loilier
et al., 2014). Data currently available has shown that the frequent
consumption of high doses of synthetic cathinones induce
tolerance, dependence, craving, and withdrawal syndrome after
sudden suspension [NDIC (National Drug Intelligence Center),
2011]. Indeed, Kehr et al. (2011) showed that mephedrone
induces a stimulation of the dopamine transmission in the
nucleus accumbens, that might be a starting point for developing
drug-addiction (Volkow et al., 2003; Di Chiara et al., 2004).
Although the typical dose range of MDPV appears to be between
5 and 30 mg in a single administration, some users reported
tolerance with the consumption of a single dose, higher than 200
mg (Coppola and Mondola, 2012). Several users have reported a
withdrawal syndrome after abrupt cessation of long-term use of
methcathinone, mephedrone and MDPV (Winstock et al., 2011).
Moreover, Gatch et al. (2013) showed that all of the cathinone
derivatives fully substituted for methamphetamine or cocaine in
drug discrimination tests. Results suggest that these drugs are
comparable to cocaine and methamphetamine, and are likely to
induce dependence (Iversen et al., 2014).
SYNTHETIC MARIJUANA AND THE
CANNABIMIMETICS
Spice and CB1 “Super Agonists”
Synthetic Cannabimimetic agents (SC), also known as
Cannabimimetics, are substances with pharmacological
properties similar to delta-9-tetrahydrocannabinol (19-
THC) assessed by in vitro and in vivo animal studies such as
binding studies and functional assays (Compton et al., 1992;
EMCDDA, 2009b). SC have been detected in “Spice,” “K2,”
and spice-like samples all over the world. Spice is a smokable
herbal mixture marketed as a safe, legal alternative to Cannabis,
composed by shredded plant material laced with a variety of SC
compounds [NIDA (National Institute on Drug Abuse), 2012].
These compounds are “smokable” since they are small (typically
20–26 carbon atoms) and highly lipophilic molecules. A few
hundred of SC of the JWH, HU, and CP series are currently
available. They retain very high cannabinoid receptor binding
affinity levels, with a dose-response efficacy significantly higher
than 19-THC itself (Brents et al., 2011; Fattore and Fratta, 2011;
Schifano et al., 2015). New legal regulations have been enacted
to control the global diffusion of Spice. As a consequence of
that, three subsequent generations of SC have been developed
based on slight modifications of the first generation compounds
such as JWH-018, CP 47,497, and HU-210 [ACMD (Advisory
Council on the Misuse of Drugs), 2009] that are full CB1 agonists
with affinities that are 4.5, 8.6, and 55 times that of 19-THC,
respectively.
Different European countries, in 2009, and some states in the
US, in 2010, banned the sale and use of first generation SC.
These regulations induced an extreme reduction of these SC in
the Spice/K2 preparations with a subsequent increase of newly
synthetized SC, thus belonging to the “second” (e.g., AM-2201,
MAM 2201, AM-694, RCS-4) and “third” (e.g., PB-22 “QUPIC,”
5F-PB-22, BB-22 “QUCHIC,” AB-PINACA) generation [ACMD
(Advisory Council on the Misuse of Drugs), 2012, 2014] in order
to avoid detection.
Several studies show that SC are remarkably different from
and more dangerous than THC. Indeed, while THC is a partial
CB1 agonist, in vitro studies have clearly shown that these
compounds are full agonists with higher potency and efficacy
as compared to 19-THC (Atwood et al., 2010, 2011; Marshell
et al., 2014). More recent studies have been shown that selected
third generation compounds, such as 5F-PB-22 and BB-22, retain
greater CB1 receptor agonist potency (five- and seven- fold,
respectively) and efficacy and a higher binding affinity (26- and
30-fold, respectively) at CB1 receptors compared to JWH-018
(De Luca et al., 2015b).
Moreover, studies performed in rats and mice showed
that many SC displayed locomotor depressant effects and a
characteristic tetrad profile at lower doses compared to 19-
THC (Chaperon and Thiébot, 1999; Wiley et al., 2012, 2014;
Gatch and Forster, 2014, 2015; Vigolo et al., 2015). In addition,
JWH-018 and its congeners are readily metabolized to a series
of cannabimimetics (Seely et al., 2012). That, together with
the presence of several different SC in Spice/K2 products
and their unpredictable dosing when consumed (Kronstrand
et al., 2014), might explain their acute severe toxicity and
even lethal medical complications in humans (Brents et al.,
2011; Papanti et al., 2013; Brents and Prather, 2014; Brewer
and Collins, 2014; Santacroce et al., 2015), leading to severe
withdrawal syndrome and dependence as well in some cases
(Zimmermann et al., 2009; Gunderson et al., 2012; Macfarlane
and Christie, 2015). In addition, clinical evidence indicates
that JWH-018 can generate/cause psychosis in vulnerable
individuals (Every-Palmer, 2011). Notably, SC misuse has
been associated with anxiety, agitation/panic attacks, paranoid
ideation, suicidal ideation, and hallucinations (Fattore and
Fratta, 2011; Wells and Ott, 2011; Thomas et al., 2012; Besli
et al., 2015), and also been related to mood, cognitive (i.e.,
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TABLE 3 | Studies related to the rewarding properties of amphetamine-like stimulants.
Substance Dosage Regimen Studies References
Desoxypipradrol Rat brain slices from the nucleus accumbens
core were exposed to desoxypipradrol (1, 3, or
10 µM) for 60 min
Dopamine efflux was electrically evoked and recorded
using fast cyclic voltammetry. Desoxypipradrol increased
the peak dopamine efflux and also slowed dopamine
re-uptake. Desoxypipradrol was more potent than
cocaine causing a seven fold increase in peak dopamine
levels and increasing dopamine re-uptake half-life 15-fold
Davidson and
Ramsey, 2011
5-APB Voltammetric studies in rat accumbens brain slices
revealed that 5-APB slowed dopamine reuptake, and at
high concentrations caused reverse transport of
dopamine
Dawson et al.,
2014
Pentedrone Pentedrone at 3 and 10 mg/kg significantly
increased conditioned place preference in
mice, while pentedrone at 0.3 mg/kg/infusion
significantly increased self-administration in rats
Pentedrone produces CPP in mice and
self-administration in rats. These results demonstrate the
abuse liability of pentedrone in both models
Hwang et al., 2015
MDPV Rats were trained to intravenously
self-administer MDPV in daily 2 hr sessions for
10 days at doses of 0.05, 0.1, or 0.2
mg/kg/infusion
MDPV has reinforcing properties and activates brain
reward circuitry, suggesting a potential for abuse and
addiction in humans
Watterson et al.,
2014
1-Benzylpiperazine 1.25, 5, and 20 mg/kg 1-benzylpiperazine induced place preference in the rat,
which indicates that the compound possesses
rewarding properties
Meririnne et al.,
2006
Methamphetamine Intravenous infusions of methamphetamine
(0.15 mg/kg) in human volunteers
Intravenous methamphetamine administration produces
activity in reward- and affect-related areas of the human
brain including the medial orbitofrontal cortex, the rostral
anterior cingulate cortex and the (ventral) striatum
Völlm et al., 2004
Mephedrone Mephedrone was quantified between 96 and
155 mg in each tablet
Mephedrone induced strong feelings of craving in most
users
Brunt et al., 2011
Mephedrone MMC was self-administered via the intravenous
route. MMC 0.1/1 mg/kg/ infusion, METH
0.01/0.3 mg/kg/ infusion
METH, but not MMC, self-administration elevated TSPO
(inflammation marker translocator protein) receptor
density in the nucleus accumbens and hippocampus,
while MMC, but not METH,self-administration decreased
striatal 5-hydroxyindolacetic acid (5-HIAA)
concentrations
Motbey et al.,
2013
R-mephedrone (R-MEPH)
S-mephedrone (S-MEPH)
Saline, R-MEPH or S-MEPH was given for 7
days using the following doses: day 1 (15
mg/kg R-MEPH/S-MEPH or saline), days 2–6
(30 mg/kg R-MEPH/S-MEPH or saline), day 7
(15 mg/kg R-MEPH/S-MEPH or saline)
Following 10 days of drug abstinence, all
groups were injected with 15 mg/kgR-MEPH
Stereospecific effects of MEPH enantiomers suggest that
the predominant dopaminergic actions of R-MEPH (i.e.,
the lack of serotonergic actions) render this stereoisomer
more stimulant-like when compared with S-MEPH
Gregg et al., 2015
Amphetamine Mephedrone
Methylone MDPV
All drugs were dissolved in physiological saline
and administered (i.p.) at doses of 0.5, 2, 5, 10
or 20 mg/kg
Mephedrone, methylone and MDPV produce CPP equal
or higher than amphetamine strongly suggesting
addictive properties
Karlsson et al.,
2014
Mephedrone
Methylenedioxymethamphetamine
Methamphetamine
Methcathinone
4-10 or 25 mg/kg s.c.per injection, 2-h
intervals, administered in a pattern used
frequently to mimic psychostimulant “binge”
treatment
Results revealed that, repeated mephedrone injections
cause a rapid decrease in striatal dopamine (DA) and
hippocampal serotonin (5-hydroxytryptamine; 5HT)
transporter function. Mephedrone also inhibited both
synaptosomal DA and 5HT uptake. Like
methylenedioxymethamphetamine, but unlike
methamphetamine or methcathinone, repeated
mephedrone administrations also caused persistent
serotonergic, but not dopaminergic, deficits. However,
mephedrone caused DA release from a striatal
suspension approaching that of methamphetamine
Hadlock et al.,
2011
(Continued)
Frontiers in Neuroscience | www.frontiersin.org 10 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
TABLE 3 | Continued
Substance Dosage Regimen Studies References
Mephedrone Motor activity experiments: rats were injected
with mephedrone (0.5, 1, 3, 5, 10, 30 mg/kg);
CPP experiments: animals received two
conditioning sessions per day, one with an
injection of mephedrone (3, 10, 30 mg/kg) and
the other with an injection of saline
In conclusion, mephedrone displayed locomotor
stimulant properties that were dependent on increased
dopamine transmission and place conditioning effects
that were suggestive of rewarding properties. Those
behavioral findings correlate well with neurochemical
studies demonstrating that mephedrone acts as a
substrate for plasma membrane monoamine
transporters, evokes transporter mediated-release of
monoamines through reversal of normal transporter flux,
and enhances extracellular levels of dopamine and
serotonin in the rat nucleus accumbens
Lisek et al., 2012
Methcathinone Methcathinone (0.1–1.0 mg/kg), All compounds facilitated ICSS (intracranial
self-stimulation) at some doses and pretreatment times,
which is consistent with abuse liability for each of these
compounds. However, efficacies of compounds to
facilitate ICSS varied, with methcathinone displaying the
highest efficacy and mephedrone the lowest efficacy to
facilitate ICSS
Bonano et al.,
2014MDPV MDPV (0.32–3.2 mg/kg),
Methylone Methylone (1.0–10 mg/kg)
Mephedrone Mephedrone (1.0–10 mg/kg)
MDPV
alpha-PVP
Self-administration: Separate groups of rats
were trained to selfadminister MDPV (N = 18;
0.05 mg/kg/infusion) or alpha-PVP (N = 9; 0.1
mg/kg/infusion, N = 18; 0.05 mg/kg/infusion).
Telemetry procedure: Seven treatment
conditions (Veh; 1, 5.6, and 10 mg/kg of
alpha-PVP and MDPV) were counterbalanced
and drugs were injected i.p. (1.0 ml/kg volume)
with a 3–4-day interval between sessions
The potency and efficacy of MDPV and alpha-PVP were
very similar across multiple assays, predicting that the
abuse liability of alpha-PVP will be significant and similar
to that of MDPV
Aarde et al., 2015
Methylone
MDPV
Mephedrone
Methamphetamine
Mice were treated with methylone (30 mg/kg),
MDPV (30 mg/kg), or mephedrone (40 mg/kg)
using a binge-like regimen comprised four
injections with a 2-h interval between each
injection. For combination treatment of mice
with methylone or MDPV with
methamphetamine, mice were treated with
varying doses of either bketoamphetamine (49
– 10, 20, or 30 mg/kg) concurrent each
injection of varying doses of methamphetamine
(49 – 2.5, 5, or 10 mg/kg). To determine if
MDPV neuroprotection would extend to
non-amphetamine neurotoxins, mice were
treated with MDPV (29 – 10 mg/kg) prior to
each of two injections of MPTP (20 mg/kg). All
injections were given via the i.p. route
The b-ketoamphetamines alone or in all possible
two-drug combinations do not result in damage to DA
nerve endings but do cause hyperthermia. MDPV
completely protects against the neurotoxic effects of
ethamphetamine while methylone accentuates it. Neither
MDPV nor methylone attenuates the hyperthermic
effects of methamphetamine. The potent neuroprotective
effects of MDPV extend to amphetamine-,
3,4-methylenedioxymethamphetamine-, and
MPTP-induced neurotoxicity. These results indicate that
b-ketoamphetamine drugs that are non-substrate
blockers of the DA transporter (i.e., MDPV) protect
against methamphetamine neurotoxicity, whereas those
that are substrates for uptake by the DA transporter and
which cause DA release (i.e., methylone, mephedrone)
accentuate neurotoxicity
Anneken et al.,
2015
MDPV
Methylone
Self-administration studies in Rats: initial
acquisition doses were 0.03 mg/kg/inj for
MDPV, 0.3 or 0.5 mg/kg/inj for methylone, and
0.5 mg/kg/inj for cocaine.
Microdialysis studies in Rats: drugs were
administered i.v.to mimic the selfadministration
route. For MDPV, rats received 0.1 mg/kg
followed by 0.3 mg/kg. For methylone, rats
received 1.0 mg/kg followed by 3 mg/kg
This study support the hypothesis that elevations in
extracellular 5-HT in the brain can dampen positive
reinforcing effects of cathinone-type drugs.
Nevertheless, MDPV and methylone are both
self-administered by rats, suggesting these drugs
possess significant abuse liability in humans
Schindler et al.,
2015
Methylone Rats were randomly assigned to one of four
groups based upon methylone dose (0.05, 0.1,
0.2, or 0.5 mg/kg per infusion)
This study reveal that methylone may possess an
addiction potential similar to or greater than MDMA, yet
patterns of self-administration and effects on brain
reward function suggest that this drug may have a lower
potential for abuse and compulsive use than prototypical
psychostimulants
Watterson et al.,
2012
(Continued)
Frontiers in Neuroscience | www.frontiersin.org 11 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
TABLE 3 | Continued
Substance Dosage Regimen Studies References
Mephedrone
Methylone
MDMA
Groups of female Wistar rats were trained to
self-administer mephedrone, methylone or
MDMA (0.5 mg/kg/inf) under a Fixed-Ratio (FR)
1 schedule of reinforcement for 14 sessions.
Following the acquisition interval, animals were
evaluated in FR (0.0, 0.125, 0.25, 0.5, 1.0, 2.5
mg/kg/inf) and Progressive-ratio- PR (0.125,
1.0 mg/kg/inf) dose-substitution procedures
The results show that female rats acquired the
self-administration of all three compounds with intakes in
mephedrone-trained rats that were significantly higher
than that of methylone-trained or MDMA-trained rats. In
doses substitution under either FR or PR contingencies,
however, the potencies of all three drugs were similar
within the original training groups. The
mephedrone-trained animals exhibited higher intakes of
all drugs during dose-substitution, indicating lasting
consequences of the training drug. Abuse liability of
these three compounds is therefore predicted to be
similar in established stimulant users but may differ in
liability if they are primary drugs of initiation
Creehan et al.,
2015
Mephedrone Mephedrone (1 or 3 mg/kg) The neurochemical and functional properties of
mephedrone resemble those of MDMA, but it also shows
an amphetamine-like effect in that it evokes a rapid
release and elimination of DA in the brain reward system,
a feature that may contribute to its potent re-inforcing
properties
Kehr et al., 2011
(+)-amphetamine
MDMA
MDMA (3 mg/kg)
(+)-amphetamine (1 mg/kg)
memory impairment, attention difficulties), neurological (i.e.,
dizziness, sensation changes, seizures, tremor) and psychotic
(i.e., agitation, aggression, catatonia, paranoia, hallucinations,
depersonalization, dissociation, prolonged psychosis, perceptual
alterations) episodes, with a higher incidence in comparison to
those seen with19-THC use (Papanti et al., 2013; Spaderna et al.,
2013; Van Amsterdam et al., 2015).
Rewarding and Reinforcing Properties of
Cannabimimetics
Recent literature shows that SC have emerged as new drugs
of abuse. As previously reported, an incredibly huge number
of SC have been detected in Marijuana substitutes (Denooz
et al., 2013; Brents and Prather, 2014; Maxwell, 2014). Being
CB1 receptor agonists with extremely high affinity, SC probably
act in brain regions where CB1 receptors are heavily expressed,
such as the amygdala, cingulate cortex, prefrontal cortex (PFC),
ventral pallidum, caudate putamen, nucleus accumbens (NAc),
ventral tegmental area (VTA), and lateral hypothalamus (Glass
et al., 1997; Wang et al., 2003). All these brain regions have
a recognized involvement in reward, addiction and cognitive
functions (Koob and Volkow, 2010). Furthermore, CB1 receptors
are located in limbic regions, such as VTA,NAc, ventral pallidum,
CeA, BNST, and PFC (Herkenham et al., 1991; Glass et al., 1997;
Wang et al., 2003); the integration of excitatory and inhibitory
inputs, coming from these structures, influence, and modulate
reward processing (Sidhpura and Parsons, 2011; Panagis et al.,
2014). Several studies in mice and rats showed that these
compounds affect the mesolimbic dopaminergic transmission
and influence conditioned behaviors (Table 4). Similar to other
drugs of abuse, THC activates dopamine (DA) transmission in
the ventral striatum in humans (Volkow et al., 2003; Bossong
et al., 2009). In addition, animal studies showed that both
1
9-THC and WIN 55.212-2, a CB1 and CB2 agonist, elicit
dopamine release in the NAc (Chen et al., 1993; Cheer et al.,
2004) with a specific activation of the NAc shell subregion
(Tanda et al., 1997; Lecca et al., 2006; De Luca et al., 2012).
The NAc plays a crucial role in brain reward circuits involved
in motivational and cognitive functions (Heimer et al., 1991;
Zahm and Brog, 1992). In particular, it has been shown that
stimulation of DA transmission in the NAc shell is directly
involved in the rewarding properties of both natural reward and
addictive drugs (Di Chiara et al., 2004). Microdialysis studies
on awake freely moving animals performed in our laboratories
showed that JWH-018, at the dose of 0.25 mg/kg i.p., increases
DA transmission in the NAc shell but not in the NAc core nor in
mPFC (Figure 4). Surprisingly, DA transmission in the NAc shell
was not stimulated after administration of lower (0.125 mg/kg
ip) or higher (0.5 mg/kg ip) doses producing an inverted U-
shape dose response curve for the effect of JWH-018 (De Luca
et al., 2015a). Further studies in mice and rats showed a similar
effect after the intraperitoneal administration of JWH-073 and
JWH-250 as well (Ossato et al., 2016), and after the intravenous
administration of BB-22 (De Luca et al., 2015b). Notably, as
previously reported by De Luca et al. (2012), THC stimulated
extracellular DA release in the NAc shell at a dose fourfold higher
than JWH-018 when administered intraperitoneally. In addition,
BB-22 stimulates NAc shell DA release at the dose of 0.01 mg/kg
iv, while THC increases extracellular DA in the same area at dose
of 0.15 mg/kg iv (Tanda et al., 1997). These results show that both
JWH-018 and BB-22 are more potent than THC in inducing NAc
shell DA release, suggesting a putative higher abuse liability of
synthetic vs. natural cannabinoids. Electrophysiological studies
show that the stimulation of DA extracellular levels in the NAc
shell by JWH-018 is thought to be due to the activation of CB1
receptors located on presynaptic GABAergic afferents directed to
VTA DA neurons, leading to a reduction of GABAA receptors
mediated inhibition of DA neuronal activity in the VTA (Lupica
and Riegel, 2005; Mátyás et al., 2008; Melis et al., 2014; De
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TABLE 4 | Studies related to the rewarding properties of cannabimimetics.
Substance Dosage Regimen Studies References
WIN 55212-2 Intravenous self-administration model in drug-naive mice
of WIN 55212-2 (0.5 and 0.1 mg/kg per injection)
WIN 55,212-2 was intravenously self-administered by mice
in a concentration-dependent manner according to a
bell-shaped curve
Martellotta et al.,
1998
HU210 Conditioned place preference (CPP) in male rats: HU210
(20, 60 and 100 µg/kg), and 19-THC (1.5 mg/kg)
HU210 and 19-THC produced aversion as expressed by
time spent in the drug-paired compartment of the CPP
apparatus
Cheer et al., 2000
WIN 55212-2 Intravenous SA in rats WIN 55,212-2 at doses ranging
from 6.25 to 50 µg/kg per injection, under a fixed-ratio 1
(FR1) schedule of reinforcement and nose-pokes as the
operant responses
Response rate depended on the drug dose available, with
maximum rates occurring at 12.5 microg/kg per injection
Fattore et al., 2001
WIN 55212-2 Fast-scan cyclic voltammetry: systemic administration at
a dose of 125 µg/kg
WIN55,212–2 enhances dopamine transients but
depresses electrically evoked release
Cheer et al., 2004
WIN 55212-2
CP 55940
HU-210
After Intracranial self-stimulation (ICSS) of the medial
forebrain bundle, rats received intraperitoneal injections
of WIN 55,212-2 (graded doses 0.1, 0.3, 1 and 3
mg/kg), CP 55,940 (graded doses 10, 30, 56 and 100
µg/kg), or HU-210 (graded doses 10, 30, 100 µg/kg)
With the exception of the highest dose of all cannabinoid
agonists tested, which significantly increased the threshold
frequency required for ICSS into the medial forebrain
bundle, all other doses of the tested drugs did not affect
ICSS thresholds. The CB1 receptor antagonist
SR141716A reversed the actions of WIN 55,212-2 and CP
55,940, but not HU-210
Vlachou et al.,
2005
WIN 55212-2 Intravenous self-administration (SA). Rats, trained for 3
weeks to self-administer WIN 55,212-2 (12.5 µg/kg) in
single daily 1-h sessions under a fixed ratio 1 (FR 1)
schedule, then switched to FR 2 for a further week.
During SA sessions, microdialysis assays were
performed every 3rd day, and then daily starting from the
13th session. Dialysate DA from the NAc shell and core
was monitored before, during, and for 30 min after SA
Response-contingent WIN 55,212-2 SA preferentially
increases the NAc shell DA output as compared to that of
the core independently from the duration of the WIN
55,212-2 exposure. Increase in NAc DA is strictly related
to WIN 55,212-2 actions because it is not observed during
extinction despite active responding
Lecca et al., 2006
WIN 55212-2 Rats received intraperitoneal injections of WIN55,212-2
(0.1, 0.3 or 1 mg/kg) for 20 subsequent days. Thresholds
for ICSS were measured before and after each injection
WIN55,212-2 (1 mg/kg) significantly increased ICSS
thresholds from the first day of administration, an effect
that remained stable across the subsequent days of
administration. These findings indicate that repeated
WIN55,212-2 administration elicited a sustained increase
in ICSS
Mavrikaki et al.,
2010
JWH-018
JWH-073
JWH-210
Adult male rats trained to discriminate 3 mg/kg
1(9)-THC or 0.3 mg/kg JWH-018 from vehicle
JWH-018, JWH-073, and JWH-210 fully substituted in
1(9)-THC-trained rats and 1(9)-THC substituted in
JWH-018-trained rats
Wiley et al., 2014
JWH-018
JWH-073
JWH-250
JWH-200
JWH-203
AM-2201
CP 47,497-C8-
homolog
These compounds were then tested for substitution in
rats trained to discriminate 1-THC (3mg/kg,
intraperitoneally)
Each of the compounds fully substituted for the
discriminative stimulus effects of 1-THC, mostly at doses
that produced only marginal amounts of rate suppression.
JWH-250 and CP 47,497-C8-homolog suppressed
response rates at doses that fully substituted for 1-THC
Gatch and Forster,
2014
CP 55940 Acute and repeated administration (7 days) of CP55,940
(0.12-0.18)mg/kg).on operant responding for electrical
brain stimulation of the medial forebrain bundle in
C57BL/6J mice
CP55,940 attenuated ICSS in a dose-related manner. This
effect was blocked by the CB1 receptor antagonist
rimonabant
Grim et al., 2015
JWH-018 Microdialysis studies in rats: 0.125 mg/kg ip 0. 25 mg/kg
ip 0. 5 mg/kg ip Rats self-administered JWH-018 (20
µg/kg/infusion) in single daily 1 h FR3 sessions.
C57BL/6 mice self-administered JWH-018 (30
µg/kg/infusion) in single daily 2 h FR1 sessions
JWH-018 0.25 mg/kg ip increases dopamine transmission
in Nac shell, but not in NAc core nor in mPFC. The lower
and the higher doses do not stimulate DA transmission so
the dose-response curve of this compound has an
inverted U-shape. Both rats and mice readily acquired two
different operant behaviors: nose-poking into an optical
switch (rats) and lever-pressing (mice)
De Luca et al.,
2015a
BB-22
5F-PB-22
5F-AKB-48
STS-135
Microdialysis studies in rats: BB-22 (0.003-0.01 mg/kg
i.v.) 5F-PB-22 (0.01 mg/kg i.v.) 5F-AKB-48 (0.1 mg/kg
i.v.) STS-135(0.15 mg/kg i.v.)
BB-22 (0.003-0.01 mg/kg i.v.) increased dialysate DA in
the accumbens shell but not in the core or in the medial
prefrontal cortex, with bell shaped dose-response curve
and an effect at 0.01 mg/kg and a biphasic time-course;
systemic AM251 (1.0 mg/kg i.p.) completely prevented the
stimulant effect of BB-22 on dialysate DA in the NAc shell.
All the other compounds increased dialysate DA in the
NAc shell at doses consistent with their in vitro affinity
De Luca et al.,
2015b
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FIGURE 4 | Effect of JWH-018 administration on DA transmission in the
NAc shell, NAc core, and mPFC. Results are expressed as mean ± SEM of
change in DA extracellular levels expressed as the percentage of basal values.
The arrow indicates the start of JWH-018 i.p. injection at the dose of 0.25
mg/kg in the NAc shell (red squares), NAc core (blue squares), and mPFC
(green squares). Solid symbol: p < 0.05 with respect to basal values; *p <
0.05 vsNAc core group; § p<0.05 vs mPFC group; (NAc shell N = 10; NAc
core N = 7; mPFC N = 11) (Two-way ANOVA, Tukey’s HSD post hoc).
Adapted from De Luca et al. (2015a).
Luca et al., 2015a). Rewarding effects of cannabimimetics have
also been assessed by different experimental paradigms such
as intracranial self-stimulation (ICSS), place conditioning tests,
drug-discrimination and intravenous self-administration (IVSA)
studies. ICSS of the medial forebrain bundle is the operant
conditioning method used in rodents to evaluate the role of the
mesolimbic dopamine pathway in rewarding behavioral effects
(Carlezon and Chartoff, 2007) and evaluating potential of abuse
(Negus and Miller, 2014). Not surprisingly, to date no data on
the effect of new SC on ICSS are available. 19-THC does not
facilitate ICSS, but has a dose-dependent inhibitory influence
on ICSS (Vlachou et al., 2007). Similarly, a depression of ICSS
is observed after the administration of WIN55212-2, CP55940,
HU210 (Antoniou et al., 2005; Vlachou et al., 2005; Mavrikaki
et al., 2010). Differences in developing tolerance to depression of
ICSS after repeated exposure to cannabinoids have been reported.
Tolerance is completely developed after repeated exposure to19-
THC (Kwilasz and Negus, 2012) but partially developed after
CP55940 (Grim et al., 2015), and not developed afterWIN55212-
2 administration (Mavrikaki et al., 2010), suggesting that the
different affinity of 19-THC vs. SC for the CB1 receptors could
play a role in developing this tolerance (Grim et al., 2015).
On the other hand, place conditioning tests in animals showed
thatWIN 55212-2 and HU210 established a robust place aversion
(CPA), reversed by the CB1 receptor antagonist/inverse agonist
SR 141716A, in a similar way as seen with 19-THC (Chaperon
et al., 1998; Cheer et al., 2000; Valjent and Maldonado, 2000).
In addition, the CB1 antagonist/inverse agonist AM281 did not
induce conditioned place preference (CPP). However, a pre-
treatment of 14 days with AM281 prior to the CPP test with
the same drug, showed significant CPP (Botanas et al., 2015).
Accordingly, it has been hypothesized that the endogenous
cannabinoid system in the brain may act as a counter-reward
system, and blocking or antagonizing this systemwould therefore
produce the reward (Sañudo-Peña et al., 1997; Botanas et al.,
2015). This could represent a limitation on the therapeutic use
of CB1 antagonist/inverse agonists (Seely et al., 2011).
The psychopharmacological effects of SC have also been
assessed by drug-discrimination studies. These experimental
paradigms represent useful tools for evaluating the abuse liability
of new drugs that might produce dependence (Solinas et al.,
2006). Drug-discrimination studies in rats have showed that
JWH-018, JWH-250 and CP 47,497-C8-homolog, UR-144, XLR-
11, AKB-48 (APINACA), PB-22 (QUPIC), 5F-PB-22, and AB-
FUBINACA fully substituted for the discriminative stimulus
effects of 19-THC (Gatch and Forster, 2014, 2015; Wiley et al.,
2014).
These studies typically serve as an integration of the results
obtained by intravenous self-administration (SA) experiments.
As for SA studies, while there is some disputable data concerning
the reinforcing properties of 19-THC based on its ability to be
persistently self-administered in squirrel monkeys (Tanda et al.,
2000) but not in rodents, there is still favorable evidence available
about SC SA. Thus it has been reported that monkeys, mice
and rats acquire and maintain WIN 55.212-2 SA (Martellotta
et al., 1998; Fattore et al., 2001; Justinova et al., 2004; Lecca
et al., 2006). Recently, it has been reported that JWH-018
is self-administered in rodents (Figure 5). In the study by
De Luca et al. (2015a) both rats and mice readily acquired
two different operant behaviors: nose-poking into an optical
switch (rats) and lever-pressing (mice). Rats self-administered
JWH-018 at the dose of 20 µg/kg/infusion in daily 1 h FR3
sessions (Figure 5A). As expected, a reduction of SA after the
injection of SR141617A (1 mg/kg ip, 30 min prior to the SA
session) was observed, consistent with the lack of JWH-018
mediated reinforcement. Intriguingly, nose-poking for JWH-
018 significantly increased from the first session (30th session,
Figure 5A) performed after the administration of SR141617A
for 2 consecutive days, confirming that these effects of JWH-
018 are mediated through cannabinoid receptors. SA behavior
did not decrease when JWH-018 was replaced by vehicle. A
control group of rats trained for vehicle, failed to acquire
SA behavior. It has been hypothesized that the absence of
extinction-like response patterns was unrelated to response-
contingent training for JWH-018 because the vehicle failed
to induce responding. We think that this probably occurred
as a result of a habit learning conditioned by JWH-018, in
fact contextual cues were sufficient to maintain responding
(De Luca et al., 2015a). This confirmed previous evidence
showing that endocannabinoid signaling through CB1 receptors
is significant for the habit formation (Hilário et al., 2007).
Indeed, in mice, CB1 receptor knockdown can enhance or blunt
habit formation, whereas 19-THC tolerance enhances habit
formation; in humans, cannabis use enhances the stimulus-
response/habit memory (for review, see Goodman and Packard,
2015).
JWH-018 self-administration studies performed in
C57BL/6 mice show that animals acquired SA at the dose
of 30 µg/kg/infusion in daily 2 h FR1 sessions (Figure 5B).
Importantly, the specificity of mice responding behavior has
been confirmed by the increase of SA under progressive-ratio
(PR) schedule of reinforcement. During extinction phase,
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FIGURE 5 | JWH-018 self-administration in rats and mice. (A) JWH-018 self-administration by Sprague-Dawley rats and involvement of CB1 cannabinoid
receptors in this behavior. Number of active nose pokes (circles) that resulted in JWH-018 infusion (20 µg/kg/infusion) or inactive ones (triangles) during each 1-h daily
session under FR1 and FR 3 during acquisition (1th to 37th sessions), extinction (38th To 47th sessions) and reacquisition (48th to 54thsessions) phases. On sessions
28th and 29th the effect of SR 141716A on the JWH-018 SA was tested. Results are expressed as mean ± SEM (N sessions 10–47 = 14, sessions 48–54 = 6) *p <
0.05 vs. inactive nose pokes; ANOVA followed by LSD post hoc test. (B) JWH-018 self-administration by C57BL/6 mice under fixed (FR1) and progressive (PR)
reinforcement schedules. Number of active lever-presses (circles) that resulted in JWH-018 infusion (30 µg/kg/inf) or inactive lever-presses (triangles) during each 2 h
daily session under FR1 (9th–15th sessions), and PR (16th session) reinforcement schedules. Results are expressed as mean ± SEM (N = 8), *p < 0.05 vs. inactive
lever- presses; ANOVA followed by LSD post hoc test. Adapted from De Luca et al. (2015a).
surprisingly, active lever-pressing did not decrease, while
inactive lever-pressing increased becoming superimposable to
the active ones. Unlike the SA experiments with rats, in these
experiments, the drug associated cues were removed after the
first three of a total of 12 sessions during the extinction phase.
However, during the JWH-018 reinstatement, SA behavior was
immediately reinstated and inactive lever-presses decreased
since the SA behavior was specifically regulated by the drug
infusion confirming the reinforcing properties of JWH-018. This
may also prove that JWH-018 alters cortical processes important
for the context updating and the automatic orientation of
attention (D’Souza et al., 2012) with consequent disruption of
cognitive functioning, emotional processing, and affective states
as different SC make in humans (Zimmermann et al., 2009).
Further research is needed to evaluate the impact of chronic
exposure to SC.
CONCLUDING REMARKS
The review of the biomedical data here presented, clearly
demonstrates the unsafe nature of these new drugs of abuse.
This is particularly alarming since adolescents seem to be
the most exposed subjects to these dangerous NPS. Indeed,
users are often unaware of the consequences of ingesting
synthetic compounds that are sold as “legal alternative” to
classical drugs, and their unexpected, sometimes fatal adverse
effects. Only awareness can reduce NPS use since stopping
their synthesis and diffusion seems to be an improbable task
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and, morbidity and mortality reports keep increasing as NPS
gain popularity worldwide. Awareness campaigns about these
substances and their devastating effects should be organized
to inform everyone, including clinicians, who should be
able to recognize symptoms of intoxication induced by NPS
(Simonato et al., 2013; Papanti et al., 2013; Schifano et al.,
2015).
Ultimately, this paper intends to be helpful to drive
governments and civil society to not underestimate theNPS issue,
and to encourage the scientific community to deeply evaluate the
pharmacology and toxicological effects of NPS and to develop
effective treatments for NPS intoxication. Additionally, this paper
intends to be useful for advising law enforcement agencies, which
need updated information for the prevention and fight against
trafficking and sale of NPS, and in the long run, hopefully
contribute to better protect public health and safety.
AUTHOR CONTRIBUTIONS
This is a review, different authors contributed as follows: CM:
Section NPS: From Chemistry to Pharmacological Effects;
Figures 1–3, Tables 1, 3, 4 . GS and CR: Section–Introduction;
MM and MM: Section–Human and Animal Studies on
amphetamine-Like Stimulant Effects: Psychoactive Effects,
Cognitive Deficits, Emotional Alterations, and Dependence
-MM: Table 2. MDL: Section–Synthetic Marijuana and the
Cannabimimetics, Section–Concluding Remarks and entire
revision of the manuscript; Figures 4, 5 and Tables 3, 4.
ACKNOWLEDGMENTS
This research has been funded by the Dipartimento Politiche
Antidroga, Presidenza del Consigliodei Ministri, Italy (projects
INSIDE-018 to MA De Luca and NS-DRUGS to M Marti
and MA De Luca), by Fondazione Banco di Sardegna
(Prot. U404.2015/AI.338.MGB Prat.2015.0713), and by
European Commission (Drug Prevention and Information
Programme 2014-16, contract no. JUST/2013/DPIP/AG/4823,
EU-MADNESS project). Some of the study cited in this review
has been performed by MA De Luca, in collaboration with
Prof. LH Parsons, at TSRI (La Jolla, CA) during the completion
of her Fulbright Research Scholar (AY 2013-2014); Dr. De
Luca would like to thank the U.S.-Italy Fulbright Commission
(www.fulbright.it) for the assistance.
REFERENCES
Aarde, S. M., Creehan, K. M., Vandewater, S. A., Dickerson, T. J., and
Taffe, M. A. (2015). In vivo potency and efficacy of the novel cathinone
α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-
administration and locomotor stimulation in male rats. Psychopharmacology
(Berl.) 232, 3045–3055. doi: 10.1007/s00213-015-3944-8
Aarde, S.M., Huang, P. K., Creehan, K.M., Dickerson, T. J., and Taffe,M. A. (2013).
The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a
potent psychomotor stimulant: self-administration and locomotor activity in
rats. Neuropharmacology 71, 130–140. doi: 10.1016/j.neuropharm.2013.04.003
ACMD (Advisory Council on the Misuse of Drugs) (2009). Review of the
ACMD, 2009 - Publications - GOV.UK. Available online at: https://www.gov.
uk/government/publications/review-of-the-acmd-2009 (Accessed October 29,
2015).
ACMD (Advisory Council on the Misuse of Drugs) (2012). Methoxetamine
report, 2012 - Publications - GOV.UK. Available at: https://www.gov.uk/
government/publications/advisory-council-on-the-misuse-of-drugs-acmd-
methoxetamine-report-2012 (Accessed October 29, 2015).
ACMD (Advisory Council on the Misuse of Drugs) (2013). Ketamine: A Review of
Use and Harm, London.
ACMD (Advisory Council on the Misuse of Drugs) (2014). IMSD 2014/ACMD
2014. Available online at: http://imsd-acmd2014.ksme.or.kr/main/ (Accessed
October 29, 2015)
Anneken, J. H., Angoa-Pérez, M., and Kuhn, D. M. (2015). 3,4-
Methylenedioxypyrovalerone prevents while methylone enhances
methamphetamine-induced damage to dopamine nerve endings: β-
ketoamphetamine modulation of neurotoxicity by the dopamine transporter.
J. Neurochem. 133, 211–222. doi: 10.1111/jnc.13048
Antoniou, K., Galanopoulos, A., Vlachou, S., Kourouli, T., Nahmias, V., Thermos,
K., et al. (2005). Behavioral pharmacological properties of a novel cannabinoid
1′,1′-dithiolane delta8-THC analog, AMG-3. Behav. Pharmacol. 16, 499–510.
doi: 10.1097/00008877-200509000-00024
Araújo, A. M., Carvalho, F., Bastos, M., de, L., Guedes de Pinho, P., and Carvalho,
M. (2015). The hallucinogenic world of tryptamines: an updated review. Arch.
Toxicol. 89, 1151–1173. doi: 10.1007/s00204-015-1513-x
Atwood, B. K., Huffman, J., Straiker, A., and MacKie, K. (2010). JWH018, a
common constituent of “Spice” herbal blends, is a potent and efficacious
cannabinoid CB 1 receptor agonist. Br. J. Pharmacol. 160, 585–593. doi:
10.1111/j.1476-5381.2009.00582.x
Atwood, B. K., Lee, D., Straiker, A., Widlanski, T. S., and Mackie, K. (2011).
CP47,497-C8 and JWH073, commonly found in “Spice” herbal blends, are
potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol.
659, 139–145. doi: 10.1016/j.ejphar.2011.01.066
Baumann, M. H., Clark, R. D., and Rothman, R. B. (2008). Locomotor stimulation
produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated
with dialysate levels of serotonin and dopamine in rat brain. Pharmacol.
Biochem. Behav. 90, 208–217. doi: 10.1016/j.pbb.2008.02.018
Baumann, M. H., Ayestas, M. A. Jr., Partilla, J. S., Sink, J. R., Shulgin, A. T.,
Daley, P. F., et al. (2012). The designer methcathinone analogs, mephedrone
and methylone, are substrates for monoamine transporters in brain tissue.
Neuropsychopharmacology 37, 1192–1203. doi: 10.1038/npp.2011.304
Baumann, M. H., Partilla, J. S., and Lehner, K. R. (2013). Psychoactive “bath salts”:
Not so soothing. Eur. J. Pharmacol. 698, 1–5. doi: 10.1016/j.ejphar.2012.11.020
Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., BolzanMariotti
Posocco, F., et al. (2014). 25C-NBOMe: preliminary data on pharmacology,
psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic
drug. Biomed Res. Int. 2014:734749. doi: 10.1155/2014/734749
Besli, G. E., Ikiz, M. A., Yildirim, S., and Saltik, S. (2015). Synthetic cannabinoid
abuse in adolescents: a case series. J. Emerg. Med. 49, 644–650. doi:
10.1016/j.jemermed.2015.06.053
Bonano, J. S., Glennon, R. A., De Felice, L. J., Banks, M. L., and Negus, S.
S. (2014). Abuse-related and abuse-limiting effects of methcathinone and
the synthetic “bath salts” cathinone analogs methylenedioxypyrovalerone
(MDPV), methylone and mephedrone on intracranial self-stimulation in rats.
Psychopharmacology (Berl). 231, 199–207. doi: 10.1007/s00213-013-3223-5
Bossong, M. G., van Berckel, B. N. M., Boellaard, R., Zuurman, L., Schuit, R.
C., Windhorst, A. D., et al. (2009). Delta 9-tetrahydrocannabinol induces
dopamine release in the human striatum. Neuropsychopharmacology 34,
759–766. doi: 10.1038/npp.2008.138
Botanas, C. J., de la Peña, J. B., Dela Pena, I. J., Tampus, R., Kim, H. J., Yoon, S.
S., et al. (2015). Evaluation of the abuse potential of AM281, a new synthetic
cannabinoid CB1 receptor antagonist. Eur. J. Pharmacol. 766, 135–141. doi:
10.1016/j.ejphar.2015.10.004
Brents, L. K., and Prather, P. L. (2014). The K2/Spice phenomenon: emergence,
identification, legislation and metabolic characterization of synthetic
Frontiers in Neuroscience | www.frontiersin.org 16 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
cannabinoids in herbal incense products. Drug Metab. Rev. 46, 72–85.
doi: 10.3109/03602532.2013.839700
Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E.,
and Prather, P. L. (2011). Phase I hydroxylated metabolites of the K2 synthetic
cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity
and activity. PLoS ONE 6:e21917. doi: 10.1371/journal.pone.0021917
Brewer, T. L., and Collins, M. (2014). A review of clinical manifestations in
adolescent and young adults after use of synthetic cannabinoids. J. Spec. Pediatr.
Nurs. 19, 119–126. doi: 10.1111/jspn.12057
Brunt, T. M., Poortman, A., Niesink, R. J. M., and van den Brink, W. (2011).
Instability of the ecstasy market and a new kid on the block: mephedrone. J.
Psychopharmacol. 25, 1543–1547. doi: 10.1177/0269881110378370
Burns, L., Roxburgh, A, Bruno, R., and Van Buskirk, J. (2014). Monitoring drug
markets in the Internet age and the evolution of drug monitoring systems in
Australia. Drug Test. Anal. 6, 840–845. doi: 10.1002/dta.1613
Carlezon, W. A. Jr., and Chartoff, E. H. (2007). Intracranial self-stimulation (ICSS)
in rodents to study the neurobiology of motivation. Nat. Protoc. 2, 2987–2995.
doi: 10.1038/nprot.2007.441
Chaperon, F., and Thiébot, M. H. (1999). Behavioral effects of cannabinoid agents
in animals. Crit. Rev. Neurobiol. 13, 243–281.
Chaperon, F., Soubrié, P., Puech, A. J., and Thiébot, M. H. (1998). Involvement of
central cannabinoid (CB1) receptors in the establishment of place conditioning
in rats. Psychopharmacology (Berl) 135, 324–332. doi: 10.1007/s002130050518
Cheer, J. F., Kendall, D. A., and Marsden, C. A. (2000). Cannabinoid receptors and
reward in the rat: a conditioned place preference study. Psychopharmacology
(Berl). 151, 25–30. doi: 10.1007/s002130000481
Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., and
Wightman, R. M. (2004). Cannabinoids enhance subsecond dopamine release
in the nucleus accumbens of awake rats. J. Neurosci. 24, 4393–4400. doi:
10.1523/JNEUROSCI.0529-04.2004
Chen, J., Marmur, R., Pulles, A., Paredes, W., and Gardner, E. L. (1993). Ventral
tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral
tegmental somatodendritic dopamine levels but not forebrain dopamine levels:
evidence for local neural action by marijuana’s psychoactive ingredient. Brain
Res. 621, 65–70. doi: 10.1016/0006-8993(93)90298-2
Compton, D. R., Johnson, M. R., Melvin, L. S., and Martin, B. R. (1992).
Pharmacological profile of a series of bicyclic cannabinoid analogs:
classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260,
201–209.
Coppola, M., and Mondola, R. (2012). Synthetic cathinones: chemistry,
pharmacology and toxicology of a new class of designer drugs of abuse
marketed as “bath salts” or “plant food.” Toxicol. Lett. 211, 144–149. doi:
10.1016/j.toxlet.2012.03.009
Corazza, O., Schifano, F., Farre, M., Deluca, P., Davey, Z., Torrens, M., et al. (2011).
Designer drugs on the internet: a phenomenon out-of-control? the emergence
ofhallucinogenic drug Bromo-Dragonfly. Curr. Clin. Pharmacol. 6, 125–129.
doi: 10.2174/157488411796151129
Corazza, O., Valeriani, G., Bersani, F. S., Corkery, J., Martinotti, G., Bersani,
G., et al. (2014). “Spice,” “kryptonite,” “black mamba”: an overview of
brand names and marketing strategies of novel psychoactive substances on
the web. J. Psychoactive Drugs 46, 287–294. doi: 10.1080/02791072.2014.
944291
Corkery, J. M., Schifano, F., and Ghodse, A. H. (2012). “Mephedrone-related
fatalities in the United Kingdom: contextual, clinical and practicalissues,” in
Pharmacology, ed L. Gallelli (Rijeka: InTech), 355–380.
Corkery, J. M., Elliott, S., Schifano, F., Corazza, O., and Ghodse, A.
H. (2013). MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-
cyclopenta[f][1,3]benzodioxol-6-amine; “sparkle”; “mindy”) toxicity: a brief
overview and update. Hum. Psychopharmacol. Clin. Exp. 28, 345–355. doi:
10.1002/hup.2298
Corkery, J. M., Claridge, H., Loi, B., Goodair, C., and Schifano, F. (2014). Drug
Related Deaths in the, UK. NPSAD Annual Report 2013. London: International
Centre for Drug Policy; St. George’s University of London.
Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T.,
Daley, P. F., et al. (2009). Dimethyltryptamine and other hallucinogenic
tryptamines exhibit substrate behavior at the serotonin uptake transporter and
the vesicle monoamine transporter. J. Neural Transm. 116, 1591–1599. doi:
10.1007/s00702-009-0308-8
Creehan, K. M., Vandewater, S. A., and Taffe, M. A. (2015). Intravenous
self-administration of mephedrone, methylone and MDMA in female rats.
Neuropharmacology 92, 90–97. doi: 10.1016/j.neuropharm.2015.01.003
Davidson, C., and Ramsey, J. (2011). Desoxypipradrol is more potent than cocaine
on evoked dopamine eﬄux in the nucleus accumbens. J. Psychopharmacol. 26,
1036–1041. doi: 10.1177/0269881111430733
Dawson, P., Opacka-Juffry, J., Moffatt, J. D., Daniju, Y., Dutta, N., Ramsey, J., et al.
(2014). The effects of benzofury (5-APB) on the dopamine transporter and 5-
HT2-dependent vasoconstriction in the rat. Prog. Neuro Psychopharmacol. Biol.
Psychiatry 48, 57–63. doi: 10.1016/j.pnpbp.2013.08.013
De Luca, M. A., Bimpisidis, Z., Melis, M., Marti, M., Caboni, P., Valentini, V.,
et al. (2015a). Stimulation of in vivo dopamine transmission and intravenous
self-administration in rats and mice by JWH-018, a Spice cannabinoid.
Neuropharmacology 99, 705–714. doi: 10.1016/j.neuropharm.2015.08.041
De Luca, M. A., Solinas, M., Bimpisidis, Z., Goldberg, S. R., and
Di Chiara, G. (2012). Cannabinoid facilitation of behavioral and
biochemical hedonic taste responses. Neuropharmacology 63, 161–168.
doi: 10.1016/j.neuropharm.2011.10.018
De Luca, M. A., Castelli, M. P., Loi, B., Porcu, A., Martorelli, M., Miliano, C.,
et al. (2015b). Native CB1 receptor affinity, intrisic activity and accumbens shell
dopamine stimulant properties of third generation spice/K2 cannabinoids: BB-
22, 5F-PB-22, 5F-AKB-48 and STS-135.Neuropharmacology. 105, 630–638. doi:
10.1016/j.neuropharm.2015.11.017
Dean, B. V., Stellpflug, S. J., Burnett, A. M., and Engebretsen, K. M. (2013). 2C or
not 2C: phenethylamine designer drug review. J. Med. Toxicol. 9, 172–178. doi:
10.1007/s13181-013-0295-x
Deluca, P., Davey, Z., Corazza, O., Di Furia, L., Farre, M., Flesland, L. H., et al.
(2012). Identifying emerging trends in recreational drug use; outcomes from
the Psychonaut Web Mapping Project. Prog. Neuro Psychopharmacol. Biol.
Psychiatry 39, 221–226. doi: 10.1016/j.pnpbp.2012.07.011
Denooz, R., Vanheugen, J.-C., Frederich, M., de Tullio, P., and Charlier, C. (2013).
Identification and structural elucidation of four cannabimimetic compounds
(RCS-4, AM-2201, JWH-203 and JWH-210) in seized products. J. Anal. Toxicol.
37, 56–63. doi: 10.1093/jat/bks095
Di Chiara, G., Bassareo, V., Fenu, S., De Luca, M. A., Spina, L.,
Cadoni, C., et al. (2004). Dopamine and drug addiction: The nucleus
accumbens shell connection. Neuropharmacology 47, 227–241. doi:
10.1016/j.neuropharm.2004.06.032
Drug Policy Department Italian Presidency of the Council of Ministers (2013a).
National Action Plan on New Psychoactive Substances, Rome.
Drug Policy Department Italian Presidency of the Council of Ministers (2013b).
New Psychoactive Substances. Rome.
Drug Policy Department Italian Presidency of the Council of Ministers (2014).
Annual Report on Drug. Rome.
D’Souza, D. C., Fridberg, D. J., Skosnik, P. D., Williams, A., Roach, B.,
Singh, N., et al. (2012). Dose-related modulation of event-related potentials
to novel and target stimuli by intravenous delta9-THC in humans.
Neuropsychopharmacology 37, 1632–1646. doi: 10.1038/npp.2012.8
EMCDDA (European Drug Report) (2014). Trends and Developments.
Available online at: http://www.emcdda.europa.eu/publications/edr/trends-
developments/2014 (Accessed November 14, 2015).
EMCDDA (2009a). Annual Report on the State of the Drugs Problem
in Europe. Available online at: http://www.emcdda.europa.eu/publications/
annual-report/2009 (Accessed October 29, 2015).
EMCDDA (2009b). Thematic Papers. Understanding the “Spice” phenomenon.
EMCDDA (European Drug Report) (2015a). Trends and Developments.
Available online at: http://www.emcdda.europa.eu/publications/edr/trends-
developments/2015 (Accessed November 14, 2015).
EMCDDA (New psychoactive substances in Europe) (2015b). An Update from
the EU Early Warning System. Available online at: http://www.emcdda.europa.
eu/publications/2015/new-psychoactive-substances (Accessed December 14,
2015).
Eshleman, A. J., Forster, M. J., Wolfrum, K. M., Johnson, R. A., Janowsky,
A., and Gatch, M. B. (2014). Behavioral and neurochemical pharmacology
of six psychoactive substituted phenethylamines: mouse locomotion, rat
drug discrimination and in vitro receptor and transporter binding and
function. Psychopharmacology (Berl.) 231, 875–888. doi: 10.1007/s00213-013-
3303-6
Frontiers in Neuroscience | www.frontiersin.org 17 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
Eshleman, A. J., Wolfrum, K. M., Hatfield, M. G., Johnson, R. A., Murphy,
K. V., and Janowsky, A. (2013). Substituted methcathinones differ in
transporter and receptor interactions. Biochem. Pharmacol. 85, 1803–1815. doi:
10.1016/j.bcp.2013.04.004
Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis:
an explorative study. Drug Alcohol Depend. 117, 152–157. doi:
10.1016/j.drugalcdep.2011.01.012
Fantegrossi, W. E., Murnane, K. S., and Reissig, C. J. (2008). The behavioral
pharmacology of hallucinogens. Biochem. Pharmacol. 75, 17–33. doi:
10.1016/j.bcp.2007.07.018
Fass, J. A., Fass, A. D., and Garcia, A. S. (2012). Synthetic Cathinones (Bath
Salts): legal status and patterns of abuse. Ann. Pharmacother. 46, 436–441. doi:
10.1345/aph.1Q628
Fattore, L., and Fratta, W. (2011). Beyond THC: The new generation
of cannabinoid designer drugs. Front. Behav. Neurosci. 5:60. doi:
10.3389/fnbeh.2011.00060
Fattore, L., Cossu, G., Martellotta, C. M., and Fratta, W. (2001). Intravenous self-
administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Psychopharmacology (Berl). 156, 410–416. doi: 10.1007/s002130100734
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, B., and
Ruoho, A. E. (2010). NIH Public Access. Science, Vol. 323, 934–937. doi:
10.1126/science.1166127
Fraser, F. (2014). New Psychoactive Substances – Evidence Review, Safer
Communities Analytical Unit. Edinburgh: Scottish Government Social
Research.
Gatch, M. B., and Forster, M. J. (2014). 19-Tetrahydrocannabinol-like
discriminative stimulus effects of compounds commonly found in K2/Spice.
Behav. Pharmacol. 25, 750–757. doi: 10.1097/FBP.0000000000000093
Gatch, M. B., and Forster, M. J. (2015). 19-Tetrahydrocannabinol-like effects of
novel synthetic cannabinoids found on the gray market. Behav. Pharmacol. 26,
460–468. doi: 10.1097/FBP.0000000000000150
Gatch, M. B., Rutledge, M. A., Carbonaro, T., and Forster, M. J. (2009).
Comparison of the discriminative stimulus effects of dimethyltryptamine with
different classes of psychoactive compounds in rats. Psychopharmacology (Berl).
204, 715–724. doi: 10.1007/s00213-009-1501-z
Gatch, M. B., Taylor, C. M., and Forster, M. J. (2013). Locomotor stimulant and
discriminative stimulus effects of “bath salt” cathinones. Behav. Pharmacol. 24,
437–447. doi: 10.1097/FBP.0b013e328364166d
German, C. L., Fleckenstein, A. E., and Hanson, G. R. (2014). Bath salts and
synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 97, 2–8.
doi: 10.1016/j.lfs.2013.07.023
Glass, M., Dragunow, M., and Faull, R. L. (1997). Cannabinoid receptors in the
human brain: a detailed anatomical and quantitative autoradiographic study
in the fetal, neonatal and adult human brain. Neuroscience 77, 299–318. doi:
10.1016/S0306-4522(96)00428-9
González, D., Ventura, M., Caudevilla, F., Torrens, M., and Farre, M. (2013).
Consumption of new psychoactive substances in a Spanish sample of research
chemical users. Hum. Psychopharmacol. 28, 332–340. doi: 10.1002/hup.2323
Goodman, J., and Packard, M. G. (2015). The influence of cannabinoids on
learning and memory processes of the dorsal striatum. Neurobiol. Learn. Mem.
125, 1–14. doi: 10.1016/j.nlm.2015.06.008
Gregg, R. A., Baumann, M. H., Partilla, J. S., Bonano, J. S., Vouga, A., Tallarida,
C. S., et al. (2015). Stereochemistry of mephedrone neuropharmacology:
enantiomer-specific behavioural and neurochemical effects in rats. Br. J.
Pharmacol. 172, 883–894. doi: 10.1111/bph.12951
Grim, T. W., Wiebelhaus, J. M., Morales, A. J., Negus, S. S., and Lichtman, A.
H. (2015). Effects of acute and repeated dosing of the synthetic cannabinoid
CP55,940 on intracranial self-stimulation in mice. Drug Alcohol Depend. 150,
31–37. doi: 10.1016/j.drugalcdep.2015.01.022
Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., and Hart,
C. L. (2012). “Spice” and “K2” Herbal Highs: a case series and systematic
review of the clinical effects and biopsychosocial implications of synthetic
cannabinoid use in humans. Am. J. Addict. 21, 320–326. doi: 10.1111/j.1521-
0391.2012.00240.x
Hadlock, G. C., Webb, K. M., McFadden, L. M., Chu, P. W., Ellis, J. D., Allen, S. C.,
et al. (2011). 4-Methylmethcathinone (mephedrone): neuropharmacological
effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 339, 530–536.
doi: 10.1124/jpet.111.184119
Heimer, L., Zahm, D. S., Churchill, L., Kalivas, P. W., and Wohltmann, C. (1991).
Specificity in the projection patterns of accumbal core and shell in the rat.
Neuroscience 41, 89–125. doi: 10.1016/0306-4522(91)90202-Y
Helander, A., Beck, O., Hägerkvist, R., and Hultén, P. (2013). Identification of
novel psychoactive drug use in Sweden based on laboratory analysis–initial
experiences from the STRIDA project. Scand. J. Clin. Lab Invest. 73, 400–406.
doi: 10.3109/00365513.2013.793817
Helander, A., Bäckberg, M., Hultén, P., Al-Saffar, Y., and Beck, O. (2014).
Detection of new psychoactive substance use among emergency room patients:
results from the Swedish STRIDA project. Forensic Sci. Int. 243, 23–29. doi:
10.1016/j.forsciint.2014.02.022
Herkenham,M., Lynn, A. B., Johnson,M. R.,Melvin, L. S., de Costa, B. R., and Rice,
K. C. (1991). Characterization and localization of cannabinoid receptors in rat
brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583.
Hermanns-Clausen, M., Kneisel, S., Szabo, B., and Auwärter, V. (2013). Acute
toxicity due to the confirmed consumption of synthetic cannabinoids:
clinical and laboratory findings. Addiction 108, 534–544. doi: 10.1111/j.1360-
0443.2012.04078.x
Hilário, M. R., Clouse, E., Yin, H. H., and Costa, R. M. (2007). Endocannabinoid
signaling is critical for habit formation. Front. Integr. Neurosci. 1:6. doi:
10.3389/neuro.07.006.2007
Hohmann, N., Mikus, G., and Czock, D. (2014). Effects and risks associated
with novel psychoactive substances: mislabeling and sale as bath salts,
spice, and research chemicals. Dtsch. Arztebl. Int. 111, 139–147. doi:
10.3238/arztebl.2014.0139
Hondebrink, L., Nugteren-van Lonkhuyzen, J. J., Van Der Gouwe, D., and
Brunt, T. M. (2015). Monitoring new psychoactive substances (NPS) in
The Netherlands: data from the drug market and the Poisons Information
Centre. Drug Alcohol Depend. 147, 109–115. doi: 10.1016/j.drugalcdep.2014.
11.033
Hwang, J.-Y., Kim, J.-S., Oh, J.-H., Hong, S.-I., Ma, S.-X., Jung, Y.-H.,
et al. (2015). The new stimulant designer compound pentedrone exhibits
rewarding properties and affects dopaminergic activity. Addict. Biol. doi:
10.1111/adb.12299. [Epub ahead of print].
IACP (International Association of Chiefs of Police) (2012). The 2012 Annual
Report of the Drug Recognition Expert Section, Alexandria, VA.
Iversen, L., Gibbons, S., Treble, R., Setola, V., Huang, X.-P., and Roth, B. L.
(2013). Neurochemical profiles of some novel psychoactive substances. Eur. J.
Pharmacol. 700, 147–151. doi: 10.1016/j.ejphar.2012.12.006
Iversen, L., White, M., and Treble, R. (2014). Designer psychostimulants:
pharmacology and differences. Neuropharmacology 87, 59–65. doi:
10.1016/j.neuropharm.2014.01.015
Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2013).
Monitoring the Future National Results on Adolescent Drug Use: Overview of
Key Findings. Bethesda, MD: National Institute on Drug Abuse, 2013. Available
online at www.monitoringthefuture.org
Justinova, Z., Tanda, G., Munzar, P., and Goldberg, S. R. (2004). The
opioid antagonist naltrexone reduces the reinforcing effects of Delta 9
tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl).
173, 186–194. doi: 10.1007/s00213-003-1693-6
Karila, L., Megarbane, B., Cottencin, O., and Lejoyeux, M. (2015). Synthetic
cathinones: a new public health problem. Curr. Neuropharmacol. 13, 12–20.
doi: 10.2174/1570159X13666141210224137
Karlsson, L., Andersson, M., Kronstrand, R., and Kugelberg, F. C. (2014).
Mephedrone, Methylone and 3,4-Methylenedioxypyrovalerone (MDPV)
induce conditioned place preference in mice. Basic Clin. Pharmacol. Toxicol.
115, 411–416. doi: 10.1111/bcpt.12253
Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., et al.
(2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine,
rapidly increases both dopamine and 5-HT levels in nucleus accumbens
of awake rats. Br. J. Pharmacol. 164, 1949–1958. doi: 10.1111/j.1476-
5381.2011.01499.x
Kelly, J. P. (2011). Cathinone derivatives: A review of their chemistry,
pharmacology and toxicology. Drug Test. Anal. 3, 439–453. doi:
10.1002/dta.313
Kersten, B. P., and McLaughlin, M. E. (2015). Toxicology and management
of novel psychoactive drugs. J. Pharm. Pract. 28, 50–65. doi:
10.1177/0897190014544814
Frontiers in Neuroscience | www.frontiersin.org 18 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
Khullar, V., Jain, A., and Sattari, M. (2014). Emergence of New Classes of
Recreational Drugs—Synthetic Cannabinoids and Cathinones. J. Gen. Intern.
Med. 29, 1200–1204. doi: 10.1007/s11606-014-2802-4
Kikura-Hanajiri, R., Kawamura, N. U. M., and Goda, Y. (2014). Changes in the
prevalence of new psychoactive substances before and after the introduction of
the generic scheduling of synthetic cannabinoids in Japan. Drug Test. Anal. 6,
832–839. doi: 10.1002/dta.1584
Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction.
Neuropsychopharmacology 35, 217–238. doi: 10.1038/npp.2009.110
Kronstrand, R., Brinkhagen, L., Birath-Karlsson, C., Roman, M., and Josefsson,
M. (2014). LC-QTOF-MS as a superior strategy to immunoassay for the
comprehensive analysis of synthetic cannabinoids in urine. Anal. Bioanal.
Chem. 406, 3599–3609. doi: 10.1007/s00216-013-7574-x
Kwilasz, A. J., and Negus, S. S. (2012). Dissociable effects of the cannabinoid
receptor agonists 19-tetrahydrocannabinol and CP55940 on pain-stimulated
versus pain-depressed behavior in rats. J. Pharmacol. Exp. Ther. 343, 389–400.
doi: 10.1124/jpet.112.197780
Kyriakou, C., Marinelli, E., Frati, P., Santurro, A., Afxentiou, M., Zaami, S.,
et al. (2015). NBOMe : new potent hallucinogens – pharmacology, analytical
methods, toxicities, fatalities : a review. Eur. Rev. Med. Pharmacol. Sci. 19,
3270–3281.
Le Roux, G., Bruneau, C., Lelièvre, B., Deguigne, M. B., Turcant, A., Harry,
P., et al. (2015). Recreational phenethylamine poisonings reported to a
French poison control center. Drug Alcohol Depend. 154, 46–53. doi:
10.1016/j.drugalcdep.2015.05.048
Lecca, D., Cacciapaglia, F., Valentini, V., and Di Chiara, G. (2006). Monitoring
extracellular dopamine in the rat nucleus accumbens shell and core during
acquisition andmaintenance of intravenousWIN 55,212-2 self-administration.
Psychopharmacology (Berl). 188, 63–74. doi: 10.1007/s00213-006-0475-3
Liechti, M. (2015). Novel psychoactive substances (designer drugs): overview
and pharmacology of modulators of monoamine signaling. Swiss Med. Wkly.
145:w14043. doi: 10.4414/smw.2015.14043
Lisek, R., Xu, W., Yuvasheva, E., Chiu, Y.-T., Reitz, A. B., Liu-Chen, L.-Y., et al.
(2012). Mephedrone (“bath salt”) elicits conditioned place preference and
dopamine-sensitive motor activation. Drug Alcohol Depend. 126, 257–262. doi:
10.1016/j.drugalcdep.2012.04.021
Loi, B., Corkery, J. M., Claridge, H., Goodair, C., Chiappini, S., Gimeno
Clemente, C., et al. (2015). Deaths of individuals aged 16-24 years in
the UK after usingmephedrone. Hum. Psychopharmacol. 30, 225–232. doi:
10.1002/hup.2423
Lessin, A. W., Long, R. F., and Parkes, M. W. (1965). Central Stimulant Actions of
Alpha-Alkyl Substituted Tryptamines inMice. Br. J. Pharmacol. Chemother. 24,
49–67. doi: 10.1111/j.1476-5381.1965.tb02079.x
López-Arnau, R., Martínez-Clemente, J., Pubill, D., Escubedo, E., and Camarasa, J.
(2012). Comparative neuropharmacology of three psychostimulant cathinone
derivatives: butylone, mephedrone and methylone. Br. J. Pharmacol. 167,
407–420. doi: 10.1111/j.1476-5381.2012.01998.x
Lupica, C. R., and Riegel, A. C. (2005). Endocannabinoid release from
midbrain dopamine neurons: a potential substrate for cannabinoid receptor
antagonist treatment of addiction. Neuropharmacology 48, 1105–1116. doi:
10.1016/j.neuropharm.2005.03.016
Maas, A., Wippich, C., Madea, B., and Hess, C. (2015). Driving under the influence
of synthetic phenethylamines: a case series. Int. J. Legal Med. 129, 997–1003.
doi: 10.1007/s00414-015-1150-1
Macfarlane, V., and Christie, G. (2015). Synthetic cannabinoid withdrawal: a
new demand on detoxification services. Drug Alcohol Rev. 34, 147–153. doi:
10.1111/dar.12225
Marshell, R., Kearney-Ramos, T., Brents, L. K., Hyatt, W. S., Tai, S., Prather,
P. L., et al. (2014). In vivo effects of synthetic cannabinoids JWH-
018 and JWH-073 and phytocannabinoid 1(9)-THC in mice: inhalation
versus intraperitoneal injection. Pharmacol. Biochem. Behav. 124, 40–47. doi:
10.1016/j.pbb.2014.05.010
Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., and Fratta, W. (1998).
Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-
naive mice. Neuroscience 85, 327–330. doi: 10.1016/S0306-4522(98)00052-9
Martinotti, G., Lupi, M., Carlucci, L., Cinosi, E., Santacroce, R., Acciavatti, T., et al.
(2015). Novel psychoactive substances: use and knowledge among adolescents
and young adults in urban and rural areas.HumPsychopharmacol. 30, 295–301.
doi: 10.1002/hup.2486
Marusich, J. A., Grant, K. R., Blough, B. E., and Wiley, J. L. (2012). Effects
of synthetic cathinones contained in “bath salts” on motor behavior and a
functional observational battery in mice. Neurotoxicology 33, 1305–1313. doi:
10.1016/j.neuro.2012.08.003
Mátyás, F., Urbán, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F.,
et al. (2008). Identification of the sites of 2-arachidonoylglycerol synthesis and
action imply retrograde endocannabinoid signaling at both GABAergic and
glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54,
95–107. doi: 10.1016/j.neuropharm.2007.05.028
Mavrikaki, M., Markaki, E., Nomikos, G. G., and Panagis, G. (2010). Chronic
WIN55,212-2 elicits sustained and conditioned increases in intracranial self-
stimulation thresholds in the rat. Behav. Brain Res. 209, 114–118. doi:
10.1016/j.bbr.2010.01.024
Maxwell, J. C. (2014). Psychoactive substances–some new, some old: a scan
of the situation in the U.S. Drug Alcohol Depend. 134, 71–77. doi:
10.1016/j.drugalcdep.2013.09.011
Melis, M., Sagheddu, C., De Felice, M., Casti, A., Madeddu, C., Spiga, S., et al.
(2014). Enhanced endocannabinoid-mediated modulation of rostromedial
tegmental nucleus drive onto dopamine neurons in sardinian alcohol-
preferring rats. J. Neurosci. 34, 12716–12724. doi: 10.1523/JNEUROSCI.1844-
14.2014
Meririnne, E., Kajos, M., Kankaanpää, A., and Seppälä, T. (2006). Rewarding
properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin.
Pharmacol. Toxicol. 98, 346–350. doi: 10.1111/j.1742-7843.2006.pto_243.x
Mills, B., Yepes, A., and Nugent, K. (2015). Synthetic Cannabinoids. Am. J. Med.
Sci. 350, 59–62. doi: 10.1097/MAJ.0000000000000466
Monteiro, M. S., Bastos, M. D. L., Guedes de Pinho, P., and Carvalho, M. (2013).
Update on 1-benzylpiperazine (BZP) party pills.Arch. Toxicol. 87, 929–947. doi:
10.1007/s00204-013-1057-x
Motbey, C. P., Clemens, K. J., Apetz, N., Winstock, A. R., Ramsey, J.,
Li, K. M., et al. (2013). High levels of intravenous mephedrone (4-
methylmethcathinone) self-administration in rats: neural consequences and
comparison with methamphetamine. J. Psychopharmacol. 27, 823–836. doi:
10.1177/0269881113490325
National Drug Intelligence Center (NDIC) (2011).National Drug Treat Assessment.
Negus, S. S., and Miller, L. L. (2014). Intracranial self-stimulation to evaluate abuse
potential of drugs. Pharmacol. Rev. 66, 869–917. doi: 10.1124/pr.112.007419
Nelson, M. E., Bryant, S. M., and Aks, S. E. (2014). Emerging drugs of abuse. Dis.
Mon. 60, 110–132. doi: 10.1016/j.disamonth.2014.01.001
Nichols, D. E. (2004). Hallucinogens. Pharmacol. Ther. 101, 131–181. doi:
10.1016/j.pharmthera.2003.11.002
NIDA (National Institute on Drug Abuse) (2012). Monitoring the Future 2012
Survey Results. Available online at: https://www.drugabuse.gov/related-
topics/trends-statistics/infographics/monitoring-future-2012-survey-results
(Accessed October 29, 2015).
Nishimura, M., and Sato, K. (1999). Ketamine stereoselectively inhibits rat
dopamine transporter. Neurosci. Lett. 274, 131–134. doi: 10.1016/S0304-
3940(99)00688-6
Ossato, A., Canazza, I., Trapella, C., Vincenzi, F., De Luca, M. A., Rimondo,
C., et al. (2016). Effect of JWH-250, JWH-073 and their interaction
on “tetrad,” sensorimotor, neurological and neurochemical responses
in mice. Prog Neuropsychopharmacol. Biol Psychiatry. 15, 31–50. doi:
10.1016/j.pnpbp.2016.01.007
Paillet-Loilier, M., Cesbron, A., Le Boisselier, R., Bourgine, J., and
Debruyne, D. (2014). Emerging drugs of abuse: current perspectives on
substituted cathinones. Subst. Abuse Rehabil. 5, 37–52. doi: 10.2147/SAR.
S37257
Palamar, J. J., Martins, S. S., Su, M. K., and Ompad, D. C. (2015).
Self-reported use of novel psychoactive substances in a US nationally
representative survey: Prevalence, correlates, and a call for new survey
methods to prevent underreporting. Drug Alcohol Depend. 156, 112–119. doi:
10.1016/j.drugalcdep.2015.08.028
Panagis, G., Mackey, B., and Vlachou, S. (2014). Cannabinoid regulation of brain
reward processing with an emphasis on the role of CB1 receptors: a step Back
into the Future. Front. Psychiatry 5:92. doi: 10.3389/fpsyt.2014.00092
Frontiers in Neuroscience | www.frontiersin.org 19 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D.,
et al. (2013). “Spiceophrenia”: a systematic overview of “spice”-related
psychopathological issues and a case report. Hum. Psychopharmacol. 28,
379–389. doi: 10.1002/hup.2312
Paus, T. (2005). Mapping brain maturation and cognitive development during
adolescence. TrendsCogn Sci. 9, 60–68. doi: 10.1016/j.tics.2004.12.008
Prosser, J. M., and Nelson, L. S. (2012). The toxicology of bath salts: a review
of synthetic cathinones. J. Med. Toxicol. 8, 33–42. doi: 10.1007/s13181-011-
0193-z
Sanders, B., Lankenau, S. E., Bloom, J. J., and Hathazi, D. (2008). “Research
chemicals”: tryptamine and phenethylamine use among high-risk youth. Subst.
Use Misuse. 43, 389–402. doi: 10.1080/00952990701202970
Santacroce, R., Corazza, O., Martinotti, G., Bersani, F. S., Valeriani, G., and
Di Giannantonio, M. (2015). Psyclones: a roller coaster of life? Hidden
synthetic cannabinoids and stimulants in apparently harmless products. Hum.
Psychopharmacol. 30, 265–271. doi: 10.1002/hup.2410
Sañudo-Peña, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., andWalker,
J. M. (1997). Endogenous cannabinoids as an aversive or counter-rewarding
system in the rat. Neurosci. Lett. 223, 125–128.
Schifano, F. (2013). “Novel psychoactive substances also known as ‘legal highs’,”
in Annual Report of the Chief MedicalOfficer. Public Mental Health Priorities:
Investing in the Evidence, ed S. C Davies (London: Department of Health), 259.
Schifano, F., Corkery, J.M., and Cuffolo, G. (2007). Smokable (“ice,” “crystal meth”)
and non smokable amphetamine-type stimulants: Clinical pharmacological and
epidemiological issues, with special reference to the UK. Ann. Ist Super. Sanita
43, 110–115.
Schifano, F., Corkery, J., Naidoo, V., Oyefeso, A., and Ghodse, H. (2010).
Overview ofamphetamine-type stimulant mortality data–UK, 1997-2007.
Neuropsychobiology 61, 122–130. doi: 10.1159/000279302
Schifano, F., Corkery, J., and Ghodse, A. H. (2012). Suspected and confirmed
fatalities associated with mephedrone (4-methylmethcathinone;‘meow
meow’) in the UK. J. Clin. Psychopharmacol. 32, 7104. doi:
10.1097/JCP.0b013e318266c70c
Schifano, F., Orsolini, L., Duccio Papanti, G., and Corkery, J. M. (2015). Novel
psychoactive substances of interest for psychiatry. World Psychiatry 14, 15–26.
doi: 10.1002/wps.20174
Schindler, C. W., Thorndike, E. B., Goldberg, S. R., Lehner, K. R., Cozzi,
N. V., Brandt, S. D., et al. (2015). Reinforcing and neurochemical
effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone
(MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male
rats. Psychopharmacology (Berl). doi: 10.1007/s00213-015-4057-0. [Epub ahead
of print].
Seely, K. A., Prather, P. L., James, L. P., and Moran, J. H. (2011). Marijuana-
based drugs: innovative therapeutics or designer drugs of abuse? Mol. Interv.
11, 36–51. doi: 10.1124/mi.11.1.6
Seely, K. A., Brents, L. K., Radominska-Pandya, A., Endres,
G. W., Keyes, G. S., Moran, J. H., et al. (2012). A major
glucuronidated metabolite of JWH-018 is a neutral antagonist at
CB1 receptors. Chem. Res. Toxicol. 39, 234–243. doi: 10.1021/tx30
00472
Sidhpura, N., and Parsons, L. H. (2011). Endocannabinoid-mediated synaptic
plasticity and addiction-related behavior. Neuropharmacology 61, 1070–1087.
doi: 10.1016/j.neuropharm.2011.05.034
Simmler, L. D., Buser, T. A., Donzelli, M., Schramm, Y., Dieu, L.-H., Huwyler, J.,
et al. (2013). Pharmacological characterization of designer cathinones in vitro.
Br. J. Pharmacol. 168, 458–470. doi: 10.1111/j.1476-5381.2012.02145.x
Simmler, L. D., Rickli, A., Schramm, Y., Hoener, M. C., and Liechti, M. E.
(2014). Pharmacological profiles of aminoindanes, piperazines, and pipradrol
derivatives. Biochem. Pharmacol. 88, 237–244. doi: 10.1016/j.bcp.2014.01.024
Simonato, P., Corazza, O., Santonastaso, P., Corkery, J., Deluca, P., Davey, Z.,
et al. (2013). Novel psychoactive substances as a novel challenge for health
professionals: results from an Italian survey. Hum. Psychopharmacol. 28,
324–331. doi: 10.1002/hup.2300
Smith, J. P., Sutcliffe, O. B., and Banks, C. E. (2015). An overview of recent
developments in the analytical detection of new psychoactive substances
(NPSs). Analyst 140, 4932–4948. doi: 10.1039/C5AN00797F
Sogawa, C., Sogawa, N., Tagawa, J., Fujino, A., Ohyama, K., Asanuma, M.,
et al. (2007). 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and
high affinity inhibitor of serotonin transporter. Toxicol. Lett. 170, 75–82. doi:
10.1016/j.toxlet.2007.02.007
Solinas, M., Panlilio, L. V., Justinova, Z., Yasar, S., and Goldberg, S. R.
(2006). Using drug-discrimination techniques to study the abuse-related
effects of psychoactive drugs in rats. Nat Protoc. 1, 1194–1206. doi:
10.1038/nprot.2006.167
Spaderna, M., Addy, P. H., and D’Souza, D. C. (2013). Spicing things up: synthetic
cannabinoids. Psychopharmacology (Berl) 228, 525–540. doi: 10.1007/s00213-
013-3188-4
Sussman, S., Skara, S., and Ames, S. L. (2008). Substance abuse among adolescents.
Substance Use Misuse 43, 1802–1828. doi: 10.1080/10826080802297302
Tanda, G., Pontieri, F. E., and Di Chiara, G. (1997). Cannabinoid
and heroin activation of mesolimbic dopamine transmission by a
common mu1 opioid receptor mechanism. Science 276, 2048–2050. doi:
10.1126/science.276.5321.2048
Tanda, G., Munzar, P., and Goldberg, S. R. (2000). Self-administration behavior is
maintained by the psychoactive ingredient of marijuana in squirrel monkeys.
Nat. Neurosci. 3, 1073–1074. doi: 10.1038/80577
Teixeira-Gomes, A., Costa, V. M., Feio-Azevedo, R., de Lourdes Bastos,
M., Carvalho, F., and Capela, J. P. S. (2014). The neurotoxicity of
amphetamines during the adolescent period. Int. J. Dev. Neurosci. 41, 1–18. doi:
10.1016/j.ijdevneu.2014.12.001
Thomas, S., Bliss, S., and Malik, M. (2012). Suicidal ideation and self-harm
following K2 use. J. Okla. State Med. Assoc. 105, 430–433.
Tittarelli, R., Mannocchi, G., Pantano, F., and Romolo, F. S. (2015). Recreational
use, analysis and toxicity of tryptamines. Curr. Neuropharmacol. 13, 26–46. doi:
10.2174/1570159X13666141210222409
Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., et al. (2015).
Novel halogenated derivates of JWH-018: behavioral and binding studies in
mice. Neuropharmacology 95, 68–82. doi: 10.1016/j.neuropharm.2015.02.008
UNODC (2013). Global Smart Update 2013. Vienna.
UNODC (2014a). Early Warning Advisory on NPS. Vienna.
UNODC (2014b).World Drugs Report. Vienna.
UNODC (2015). The Challenge of Synthetic Drugs in East and South-East
Asia and Oceania. Trends and Patterns of Amphetamine-type Stimulants and
New Psychoactive Substances. World Drugs Report. Wien: Global SMART
Programme.
Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F., and
Carvalho, M. (2014). Khat and synthetic cathinones: a review. Arch. Toxicol.
88, 15–45. doi: 10.1007/s00204-013-1163-9
Valjent, E., and Maldonado, R. (2000). A behavioural model to reveal place
preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 147,
436–438. doi: 10.1007/s002130050013
Van Amsterdam, J., Brunt, T., and van den Brink, W. (2015). The adverse health
effects of synthetic cannabinoids with emphasis on psychosis-like effects. J.
Psychopharmacol. 29, 254–263. doi: 10.1177/0269881114565142
Vlachou, S., Nomikos, G. G., and Panagis, G. (2005). CB1 cannabinoid
receptor agonists increase intracranial self-stimulation thresholds in the rat.
Psychopharmacology (Berl) 179, 498–508. doi: 10.1007/s00213-004-2050-0
Vlachou, S., Nomikos, G. G., Stephens, D. N., and Panagis, G. (2007). Lack
of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the
intracranial self-stimulation and conditioned place preference procedures
in rodents. Behav. Pharmacol. 18, 311–319. doi: 10.1097/FBP.0b013e328
2186cf2
Volkow, N. D., Fowler, J. S., and Wang, G.-J. (2003). The addicted human
brain: insights from imaging studies. J. Clin. Invest. 111, 1444–1451. doi:
10.1172/JCI18533
Völlm, B. A., de Araujo, I. E., Cowen, P. J., Rolls, E. T., Kringelbach, M. L.,
Smith, K. A., et al. (2004). Methamphetamine activates reward circuitry in
drug naïve human subjects. Neuropsychopharmacology 29, 1715–1722. doi:
10.1038/sj.npp.1300481
Wang, X., Dow-Edwards, D., Keller, E., and Hurd, Y. L. (2003). Preferential
limbic expression of the cannabinoid receptor mRNA in the human fetal brain.
Neuroscience 118, 681–694.
Watterson, L. R., Hood, L., Sewalia, K., Tomek, S. E., Yahn, S., Johnson, C. T.,
et al. (2012). The reinforcing and rewarding effects of methylone, a synthetic
cathinone commonly found in “Bath Salts.” J. Addict. Res. Ther. pii (Suppl.
9):002. doi: 10.4172/2155-6105.S9-002
Frontiers in Neuroscience | www.frontiersin.org 20 April 2016 | Volume 10 | Article 153
Miliano et al. Addictive Properties of NPS
Watterson, L. R., Kufahl, P. R., Nemirovsky, N. E., Sewalia, K., Grabenauer,
M., Thomas, B. F., et al. (2014). Potent rewarding and reinforcing
effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone
(MDPV). Addict. Biol. 19, 165–174. doi: 10.1111/j.1369-1600.2012.
00474.x
Wells, D. L., and Ott, C. A. (2011). The “new” marijuana. Ann. Pharmacother. 45,
414–417. doi: 10.1345/aph.1P580
Welter-Luedeke, J., and Maurer, H. H. (2015). New psychoactive substances. Ther.
Drug Monit. 38, 4–11. doi: 10.1097/FTD.0000000000000240
Whelpton, R. (2007). Speed, Ecstasy, Ritalin: the science of amphetamines. Br. J.
Clin. Pharmacol. 63, 763–763. doi: 10.1111/j.1365-2125.2006.02818.x
Wikström, M., Holmgren, P., and Ahlner, J. (2004). A2 (N-benzylpiperazine) a
new drug of abuse in Sweden. J. Anal. Toxicol. 28, 67–70. doi: 10.1093/jat/28.
1.67
Wiley, J. L., Marusich, J. A., Martin, B. R., and Huffman, J. W. (2012). 1-
Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles
in mice. Drug Alcohol Depend. 123, 148–153. doi: 10.1016/j.drugalcdep.2011.
11.001
Wiley, J. L., Marusich, J. A., and Huffman, J. W. (2014). Moving around
the molecule: relationship between chemical structure and in vivo activity
of synthetic cannabinoids. Life Sci. 97, 55–63. doi: 10.1016/j.lfs.2013.
09.011
Winstock, A. R., and Barratt, M. J. (2013). The 12-month prevalence and nature
of adverse experiences resulting in emergency medical presentations associated
with the use of synthetic cannabinoid products. Hum. Psychopharmacol. Clin.
Exp. 28, 390–393. doi: 10.1002/hup.2292
Winstock, A., and Schifano, F. (2009). “Disorders relating to the use of ecstasy,
other ‘party drugs’ and khat,” in New Oxford Textbook of Psychiatry eds
M. Gelder, N. Andreasen, J. J. Lopez-Ibor, and J. Geddes (Oxford: Oxford
University Press), 494–502.
Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O., and Schifano,
F. (2011). Mephedrone, new kid for the chop? Addiction 106, 154–161. doi:
10.1111/j.1360-0443.2010.0330.x
Wood, D. M., Heyerdahl, F., Yates, C. B., Dines, A. M., Giraudon, I., and Hovda, K.
E. (2014). The european drug emergencies network (Euro-DEN). Clin. Toxicol.
(Phila). 52, 239–241. doi: 10.3109/15563650.2014.898771
Wood, D. M., Sedefov, R., Cunningham, A., and Dargan, P. I. (2015). Prevalence of
use and acute toxicity associated with the use of NBOMe drugs. Clin. Toxicol.
53, 85–92. doi: 10.3109/15563650.2015.1004179
Wright, M. J. Jr., Angrish, D., Aarde, S. M., Barlow, D. J., Buczynski,
M. W., Creehan, K. M., et al. (2012). Effect of ambient temperature
on the thermoregulatory and locomotor stimulant effects of 4-
methylmethcathinone in wistar and sprague-dawley rats. PLoS ONE 7:e44652.
doi: 10.1371/journal.pone.0044652
Zahm, D. S., and Brog, J. S. (1992). On the significance of subterritories in the
“accumbens” part of the rat ventral striatum. Neuroscience 50, 751–767. doi:
10.1016/0306-4522(92)90202-D
Zawilska, J. B. (2015). “Legal Highs”–An Emerging Epidemic of Novel
Psychoactive Substances. Int. Rev. Neurobiol. 120, 273–300. doi:
10.1016/bs.irn.2015.02.009
Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel,
R., and Schulz, K. (2009). Withdrawal phenomena and dependence syndrome
after the consumption of “spice gold.” Dtsch. Arztebl. Int. 106, 464–467. doi:
10.3238/arztebl.2009.0464
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Miliano, Serpelloni, Rimondo, Mereu, Marti and De Luca. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 21 April 2016 | Volume 10 | Article 153
